[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2284
1. Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, Jain P, Bishop L, Horwich A, Catovsky D: Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer; 2003 Jul 7;89(1):36-42
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
  • A grading system (grades 1-3) for follicular lymphoma (FL) is used in the WHO classification for lymphoid malignancies based on the absolute number of centroblasts in the neoplastic follicles.
  • Grade 3 FL is further subdivided into 3a and 3b depending on the presence or absence of centrocytes.
  • A total of 231 patients with FL, referred from 1970 to 2001, were identified from our prospectively maintained database.
  • Follicular lymphoma grades 1, 2 and 3 accounted for 92, 68 and 55 patients, respectively.
  • No significant overall survival (OS) differences were observed among FL grades 1-3 (log rank P=0.25) or between grades 3a and 3b (log rank P=0.20).
  • No significant failure-free survival (FFS) differences were observed among FL grades 1-3 (log rank P=0.72) or between grades 3a and 3b (log rank P=0.11).
  • First-line anthracyclines did not influence OS or FFS (log rank P=0.86, P=0.58, respectively) in patients with FL grade 3.
  • There are long-term survivors among patients with FL grade 3 with a continuing risk of relapse.
  • Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy in our series.
  • The role of anthracyclines should be further evaluated in large randomised studies.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Neoplasm Staging
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials as Topic. Databases, Factual. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Dec;11(12):1551-6 [11205462.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):273-85 [10439364.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Hematol Oncol. 1983 Apr-Jun;1(2):187-92 [6376315.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):857-61 [3802044.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):218-24 [8426197.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1349-57 [8021725.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3671-8 [7780151.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1654-63 [9193366.001]
  • [Cites] Hematol Oncol Clin North Am. 1997 Oct;11(5):893-900 [9336720.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2202-7 [10090928.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • (PMID = 12838297.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  • [Other-IDs] NLM/ PMC2394229
  •  go-up   go-down


2. Damaj G, Braud AC, Hermine O: [Anemia and chemotherapy of malignant hemopathies]. Bull Cancer; 2003 Apr;90 Spec No:S144-51
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anemia and chemotherapy of malignant hemopathies].
  • [Transliterated title] Anémie et chimiothérapie des hémopathies malignes.
  • Anemia is a frequent symptom encountered in hematological malignancies at diagnosis or in the course of the disease.
  • Allogeneic transfusions were, until recently, the only treatment available and used only for severe anemia.
  • Erythropoietin is currently an important alternative especially for treatment and even to prevent severe anemia.
  • It has been assessed for the treatment of chemotherapy related anemia in NHL, myeloma and CLL with a significant reduction of blood transfusions and prevention of grade 3-4 anemia in 51% of patients.
  • In the setting of allogeneic bone marrow transplantation, it reduces the time to red cell engraftment and probably the number of blood cell unit per patient in contrast with autologous stem cell transplant.
  • [MeSH-major] Anemia. Erythropoietin / therapeutic use. Hematologic Neoplasms / drug therapy
  • [MeSH-minor] Hematologic Diseases / complications. Hematopoietic Cell Growth Factors / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Myelodysplastic Syndromes / complications. Recombinant Proteins

  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856426.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hematopoietic Cell Growth Factors; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  • [Number-of-references] 39
  •  go-up   go-down


3. Hans CP, Weisenburger DD, Vose JM, Hock LM, Lynch JC, Aoun P, Greiner TC, Chan WC, Bociek RG, Bierman PJ, Armitage JO: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood; 2003 Mar 15;101(6):2363-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
  • Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course.
  • On the basis of possible biologic differences, the new World Health Organization (WHO) classification of lymphoma suggests further subdivision of FL3 into grades 3a and 3b and states that the percentage of involvement by diffuse large B-cell lymphoma (DLBCL) should also be reported.
  • Therefore, we studied 190 newly diagnosed patients with lymph node-based FL3 who received anthracycline-containing combination chemotherapy.
  • The follicular component was subclassified as grade 3a (FL3a) or grade 3b (FL3b) according to the WHO criteria, or as follicular large cleaved cell type (FLC).
  • However, those cases with a predominant diffuse component (> 50% diffuse) had a significantly worse overall survival (P =.0037) and event-free survival (P =.012).
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Follicular / mortality. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Mitoxantrone / therapeutic use. Prednisolone / therapeutic use. Prednisone / therapeutic use. Procarbazine / therapeutic use. Prognosis. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12424193.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA36727
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol; COP-BLAM protocol; MCOP protocol
  •  go-up   go-down


Advertisement
4. Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, Ford JM, Delgado DJ, Fridman M, Carter WB: Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park); 2001 Oct;15(10):1296-306; discussion 1310-1, 1314
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
  • Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-Hodgkin's lymphoma (NHL).
  • Of the 653 patient records reviewed, 90 (14%) omitted an anthracycline or mitoxantrone (Novantrone) from primary therapy.
  • Of 181 advanced-stage patients with responsive disease, 28 (15%) failed to receive at least six treatment cycles.
  • Overall, 283 (43%) of 653 patients potentially received suboptimal chemotherapy due either to choice of regimen or chemotherapy delivered.
  • Patient age > or = 65 years and cardiac comorbidity appeared to have the greatest influence on a physician's decision regarding chemotherapy administration.
  • Among the 492 patients who received CHOP or CNOP, 235 (48%) experienced a delay or reduction in chemotherapy dose (usually neutropenia-related), 100 (20%) developed mucositis, and 116 (24%) were hospitalized for febrile neutropenia.
  • Growth factor was administered to 261 patients (53%), and its primary prophylactic use was associated with a significant reduction in the incidence of hospitalizations for febrile neutropenia in all patient subgroups receiving appropriate chemotherapeutic dose intensity (P = .02).
  • This assessment of chemotherapy delivery to patients with intermediate-grade NHL showed significant variation from current standards.
  • Further analysis of factors influencing chemotherapy delivery might improve therapeutic outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Growth Substances / therapeutic use. Humans. L-Lactate Dehydrogenase / analysis. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Neutropenia / chemically induced. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Reference Values. Retrospective Studies. Severity of Illness Index. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702959.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol; MCOP protocol
  •  go-up   go-down


5. Coiffier B: Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin Oncol; 2003 Feb;30(1S2):21-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly.
  • Rituximab is an anti-CD20 chimeric monoclonal antibody that has shown substantial activity in indolent non-Hodgkin's lymphoma (NHL).
  • Recent data indicate that the clinical benefits achieved in the treatment of indolent NHL are mirrored in aggressive NHL.
  • Diffuse large B-cell lymphoma is the most common form of aggressive NHL and accounts for approximately 40% of all NHL cases.
  • Although rapidly fatal if left untreated, diffuse large B-cell lymphoma is responsive to chemotherapy.
  • CHOP has been the gold standard of care in aggressive NHL for over 20 years and, until recently, efforts to improve efficacy have not resulted in substantial increases in clinical benefit.
  • However, long-term survival is seen in less than 50% of patients, highlighting the need for novel therapeutic strategies.
  • The activity of single-agent rituximab in pilot trials in the aggressive setting and its potential to sensitize tumor cells to the effects of chemotherapy, together with its non-overlapping safety profile, have encouraged investigators to combine rituximab with CHOP.
  • The addition of rituximab to CHOP chemotherapy has achieved impressive survival benefits in elderly patients with untreated diffuse large B-cell lymphoma compared with CHOP alone.
  • Importantly, improved response and survival were achieved with minimal additional toxicity, suggesting that immunochemotherapy provides a new standard of care in aggressive NHL.
  • This article reviews the activity of rituximab in aggressive lymphoma and highlights its potential in both previously untreated and relapsed disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2003 Elsevier Science (USA). All rights reserved.
  • (PMID = 28140217.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Boulanger E, Daniel MT, Agbalika F, Oksenhendler E: Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol; 2003 Jul;73(3):143-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma.
  • Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities.
  • Most patients are HIV-infected homosexual men with severe immunosuppression and other KSHV/HHV8-associated diseases such as Kaposi's sarcoma (KS).
  • The prognosis is poor with a median survival of less than 6 months in most cohorts.
  • High-dose chemotherapy regimens are warranted to improve complete remission rate and survival.
  • Seven patients with AIDS-associated PEL were treated with a combined chemotherapy including high-dose methotrexate followed by leucovorin rescue.
  • Upon diagnosis, 6 patients received antiretroviral therapy, which was maintained during chemotherapy in 5 of them.
  • At time of analysis, 3 out of 7 patients were in complete remission 18, 26, and 78 months after PEL diagnosis.
  • Three patients died with a progressive PEL at 22, 67, and 153 days after diagnosis, and 1 patient died 9 months after PEL diagnosis with a MCD-associated plasmablastic NHL.
  • Complete remission was obtained in 3 out of 7 patients treated for AIDS-associated PEL with combined chemotherapy containing high-dose methotrexate.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Herpesviridae Infections / drug therapy. Herpesvirus 8, Human. Methotrexate / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Adult. Antigens, CD / blood. DNA, Viral / isolation & purification. European Continental Ancestry Group. France. HIV Infections / complications. HIV Infections / drug therapy. Homosexuality, Male. Humans. Immunophenotyping. Male. Middle Aged. Pleural Effusion / pathology. Prognosis. RNA, Viral / blood. Treatment Outcome. Viral Load


7. Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist; 2007 Dec;12(12):1416-24
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
  • BACKGROUND: There is a misconception that elderly cancer patients cannot tolerate standard doses of chemotherapy because of the frequency and severity of myelosuppressive complications.
  • METHODS: Patients (> or = 65 years of age) with either solid tumors or non-Hodgkin's lymphoma (NHL) were randomly assigned to receive pegfilgrastim either proactively or reactively.
  • Proactive pegfilgrastim use resulted in a significantly lower incidence of febrile neutropenia for both solid tumor and NHL patients compared with reactive use.
  • Antibiotic use was lower for solid tumor patients receiving proactive pegfilgrastim and equivalent in the two NHL groups.
  • Proactive pegfilgrastim use effectively produced a lower incidence of febrile neutropenia and related events in elderly patients with either solid tumors or NHL receiving an array of mild to moderately neutropenic chemotherapy regimens.
  • Pegfilgrastim should be used proactively in elderly cancer patients to support the optimal delivery of standard chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Neoplasms / drug therapy. Neutropenia / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Drug-Related Side Effects and Adverse Reactions. Female. Filgrastim. Humans. Male. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165618.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


8. Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M, Gazzard B, Powles T: Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood; 2008 Apr 15;111(8):3986-90
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma.
  • The late effects of chemotherapy on immunologic parameters in AIDS-related non-Hodgkin lymphoma (NHL) have not been described.
  • From a cohort of 105 consecutive patients treated with infusional chemotherapy and highly active antiretroviral therapy (HAART), 68 survived more than 3 months following the end of chemotherapy.
  • During chemotherapy, there were statistically significant falls in CD4 (helper T), CD8 (cytotoxic T), and CD19 (B) cell populations but no changes in the CD56 (natural killer [NK]) cell population.
  • Among the 68 survivors, there were statistically significant increases in CD4, CD8, CD19, and CD56 cell populations during the first year of follow up, compared with the values at the start of chemotherapy.
  • During the second year of follow up, there were further statistically significant rises in CD4 and CD19 cell populations, compared with the values at 12 months after chemotherapy.
  • During 244 years of follow-up since chemotherapy in these 68 survivors, 7 second primary tumors and 8 opportunistic infections were diagnosed.
  • Chemotherapy and concomitant HAART for AIDS-related NHL does not cause prolonged suppression of lymphocyte subsets.
  • These data should provide reassurance regarding the long-term consequences of chemotherapy in these individuals.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Anti-HIV Agents / adverse effects. Anti-HIV Agents / pharmacology. Anti-HIV Agents / therapeutic use. Cell Count. Female. HIV-1 / drug effects. Humans. Lymphocyte Subsets / drug effects. Lymphocyte Subsets / pathology. Lymphocyte Subsets / virology. Male. Middle Aged. Survival Rate. Viral Load


9. Coiffier B: Effective Immunochemotherapy For Aggressive Non-Hodgkin's Lymphoma. Semin Oncol; 2004 Feb;31 Suppl 2:7-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective Immunochemotherapy For Aggressive Non-Hodgkin's Lymphoma.
  • In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered the gold standard treatment for aggressive non-Hodgkin's lymphoma (NHL).
  • CHOP is only curative in approximately 40% of patients, and numerous clinical trials have been carried out to find a treatment that can increase the cure rate.
  • For some patients with aggressive NHL, it is possible to improve survival by intensification of chemotherapy compared with standard CHOP.
  • Early high-dose treatment/autologous stem cell transplantation may be beneficial for some patients, but not in patients with low-risk disease or those over 60 years of age who are not eligible for autologous stem cell transplantation.
  • The most striking and consistent improvement over CHOP chemotherapy in the treatment of aggressive NHL is the addition of rituximab.
  • A phase III randomized study Groupe d'Etudes des Lymphomes de l'Adulte (GELA LNH 98.5) compared rituximab plus CHOP with CHOP alone in treatment of 399 patients aged 60 to 80 years of age with aggressive NHL.
  • The addition of rituximab to CHOP also overcame bcl-2-associated resistance to chemotherapy.
  • There is no standard chemotherapy regimen for relapsed patients, but results from several single-arm studies suggest the addition of rituximab will increase the complete response rate to many different salvage regimens.
  • The development of newer treatment strategies incorporating rituximab may improve the cure rate further.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140109.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Seymour JF: New Treatment Approaches To Indolent Non-Hodgkin's Lymphoma. Semin Oncol; 2004 Feb;31 Suppl 2:27-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New Treatment Approaches To Indolent Non-Hodgkin's Lymphoma.
  • Disseminated indolent non-Hodgkin's lymphoma (NHL) is considered incurable with conventional chemotherapy regimens, and more than 50% of patients die within 5 years of their first relapse.
  • Therefore, newer treatment approaches have been used to try to improve survival and ultimately provide a cure for patients with disseminated indolent NHL.
  • The anti-CD20 monoclonal antibody rituximab has been extensively evaluated and is now an integral component of many treatment strategies.
  • The activity of rituximab was first shown in the pivotal trial in patients with relapsed and refractory low-grade and follicular lymphoma.
  • More recent studies have shown somewhat higher activity of rituximab when used first-line, with further improvements with maintenance therapy.
  • Rituximab in combination with chemotherapy has been shown to achieve high response rates, and two prospective randomized studies from the German Low-grade Lymphoma Study Group have shown significantly higher response rates and longer survival for patients receiving rituximab concurrently with chemotherapy compared with those receiving chemotherapy alone.
  • Further data from ongoing phase III studies are still needed to determine whether rituximab can help alter the natural history of indolent NHL, and longer follow-up of these patients will help determine the optimal role for rituximab in treatment of indolent NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140107.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gisselbrecht C, Mounier N: Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma. Semin Oncol; 2004 Feb;31 Suppl 2:12-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma.
  • The prognosis is poor for patients relapsing following treatment with standard chemotherapy for aggressive non-Hodgkin's lymphoma.
  • High-dose therapy and autologous stem cell transplantation is a potential curative approach for these patients.
  • The primary aim of second-line therapy is the attainment of a complete response, because response rate is predictive of outcome following autologous stem cell transplantation.
  • Because the addition of rituximab to chemotherapy regimens leads to improved complete response rates compared with chemotherapy alone, it should be considered as an important component of second-line regimens for aggressive NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140103.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH: Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol; 2002 Feb;29(1S2):36-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
  • Non-Hodgkin's lymphoma (NHL) is composed of a group of lymphoid malignancies that has been increasing in incidence at an annual rate of 4% to 7% over the last 20 years in both the United States and Europe.
  • The reasons for this rise in incidence in NHL are not yet defined but most likely involve environmental exposures.
  • Low-grade and follicular lymphomas account for approximately 40% of the incidences of NHL in the United States.
  • While patients with intermediate- and high-grade lymphomas are potentially curable with combination chemotherapy, low-grade and follicular lymphomas are still considered to be essentially incurable with standard therapy.
  • Although low-grade lymphomas characteristically respond well to treatment with chemotherapeutic agents, the disease typically follows a course of recurrent relapse and progressively shorter remissions, and ultimately death from lymphoma.
  • Median survival for patients with low-grade lymphoma is 6.2 years from diagnosis and just 5 years from time of first relapse.
  • Therefore, novel therapeutic strategies are urgently needed for these patients.
  • One approach to the development of innovative strategies for treatment of NHL has been the generation of monoclonal antibodies to specific B-cell antigens expressed on NHL cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2002 W.B. Saunders Company. All rights reserved.
  • (PMID = 28140090.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH: Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Am Coll Nutr; 2007 Feb;26(1):49-56
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).
  • METHODS: The above parameters were analyzed in 105 ALL and NHL and 108 age and sex-matched controls.
  • Comparisons were made to stage of treatment (maintenance 6 with post-therapy), type of treatment (chemotherapy and radiation with only chemotherapy) and type of malignancy (ALL with NHL).
  • RESULTS: Only serum albumin in patients included at Maintenance(6) was significantly higher (t = 2.31, p = 0.05) than post-therapy patients.
  • No significant difference in serum values was observed by type of treatment.
  • Only total cholesterol was significantly higher in NHL patients than in ALL patients (t = 1.954, p = 0.05).
  • CONCLUSION: The results of the present study indicate that cancer and its treatment did not have any long-lasting effect on serum albumin, total cholesterol, retinol, zinc and hemoglobin.
  • A higher percentage of patients with low serum retinol levels may also be attributed to the possibility of urinary losses of retinol that occur during episodes of infection while on immunosuppressive anti-cancer drug therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood


14. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE: The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol; 2008 Mar;19(3):553-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
  • BACKGROUND: The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied.
  • PATIENTS AND METHODS: We retrospectively reviewed the records of 45 patients with follicular grade 3 lymphoma who were treated with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) at The University of Texas MD Anderson Cancer Center.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083690.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


15. Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose JM, Armitage JO: Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol; 2006 Jun;17(6):920-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.
  • BACKGROUND: The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3).
  • MATERIALS AND METHODS: Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study.
  • RESULTS: Patients with FL3 and a diffuse component of >50% had the worst outcome, with a hazard ratio of dying of 2.2 (95% CI 1.4-3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95% CI 1.02-2.5) compared with FL3 with a diffuse component of < or =50% by multivariate analysis (P = 0.0026).
  • However, there were no differences in the cumulative incidence of relapse/progression or lymphoma-specific/treatment-related mortality between the two age groups.
  • CONCLUSIONS: Less than half of the patients with FL3 and a diffuse component of < or =50% treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years.
  • Older patients should be offered the same aggressive chemotherapy as younger patients.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524969.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Frampton JE, Keating GM: Spotlight on pegfilgrastim in chemotherapy-induced neutropenia. BioDrugs; 2005;19(6):405-7
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
  • Its approved indication in the US is to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.A single subcutaneous injection of pegfilgrastim once per chemotherapy cycle was more effective than placebo as an adjunct to moderately myelosuppressive chemotherapy for breast cancer, no less effective than daily injections of filgrastim as an adjunct to highly myelosuppressive chemotherapy for breast cancer, and as effective as daily filgrastim as an adjunct to chemotherapy for lymphoma (predominantly non-Hodgkin lymphoma [NHL]) and acute myeloid leukemia.
  • Pegfilgrastim has also successfully supported delivery of dose-dense chemotherapy, stem cell mobilization, and stem cell transplantation after high-dose chemotherapy in patients with non-myeloid or myeloid malignancies.
  • By offering a convenient alternative to daily filgrastim, once-per-cycle administration of pegfilgrastim has the potential to simplify the management of chemotherapy-induced neutropenia, further improve patient health-related quality of life, and reduce total treatment costs in breast cancer and NHL, and possibly other cancer settings.
  • Pegfilgrastim should, likewise, permit simplification of G-CSF-based stem cell mobilization and transplantation procedures.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Granulocyte Colony-Stimulating Factor / therapeutic use. Neutropenia / prevention & control
  • [MeSH-minor] Filgrastim. Humans. Neoplasms / drug therapy. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16392893.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  • [Number-of-references] 32
  •  go-up   go-down


17. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • The aim of this study was to compare the time of engraftment and mortality rate and cost of neutropenic treatment in outpatient versus inpatient autologous stem cell transplantation (SCT).
  • METHODS: 9 outpatients (5 HL, 2 NHL, and 2 AML) were compared with 32 inpatients (15 HL, 8 NHL, and 9 AML; for whom the outpatient facilities were not ready) from May 2008 to December 2008.
  • They received conditioning regimen (CEAM for NHL and HL, busulfan and etoposide for AML) and stem cell infusion in hospital.
  • The day after SCT, outpatient group were discharged and followed by outpatient SCT team, and to be re-hospitalized in case of febrile neutropenia, after sepsis workup and performing chest x-ray, they were received the first dose of antibiotic in hospital and treatment continued in home.
  • RESULTS: For outpatients and inpatients, median time to WBC engraftment was 11 and 12 days (p = 0.03), time to PLT engraftment was 15 and 25 days (p = 0.20), number of transfused single donor PLT was 3 and 4.5 units (p = 0.21), duration of neutropenic fever was 6 and 9 days (p = 0.001), duration of hospitalization (after SCT) 0 and 16 (p < 0.001), respectively.
  • For inpatient group the cost of drugs, just for neutropenic fever antibiotic therapy was six times than outpatient group.
  • CONCLUSIONS: Results show that out-patient autologous SCT in malignant hematologic disorders is feasible and comparable with inpatient protocol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bascioni R, Giorgi F, Safi M, Giustini L, De Signoribus G, Silva R: Chemotherapy in very elderly cancer patients (85 years and over): A retrospective study. J Clin Oncol; 2009 May 20;27(15_suppl):e20632

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in very elderly cancer patients (85 years and over): A retrospective study.
  • Since very elderly (85 years and over) cancer pts are generally excluded from clinical trials, few data are available about tolerability of chemotherapy in this population.
  • METHODS: We conducted a retrospective analysis of cancer pts aged 85 years and over receiving chemotherapy for advanced disease in the years 2005-2007 in three Oncology Unit of the Regione Marche, Italy.
  • RESULTS: We identified 50 patients (26 males, 24 females) with a mean age of 86.4 (range 85-95), ECOG PS 0 (4 pts) 1 (25 pts) 2 (13 pts) 3 (8 pts).
  • Type of cancer (pts): NSCLC (13), colorectal (11), breast (5), prostate (4), gastric (3), NHL (3), bladder (2), head-neck (2), ovarian (2), vulvar (1), skin (1), pancreas (1), GIST (1), UPT (1).
  • The median number of cycles in first line chemotherapy were 6 (1-44); 20 pts received 2 or more lines of chemotherapy (range 2-5).
  • Most used drugs were: vinorelbine os or iv (14 pts), capecitabine (9 pts), gemcitabine (7 pts).
  • Ten partial responses were observed; main toxicities were: grade 3-4 neutropenia (10 %), grade 3 diarrhea (5 %), and 1 pts had grade 3 hand-foot syndrome.
  • No treatment related deaths were observed.
  • CONCLUSIONS: Very elderly cancer pts (85 years and over) in good PS and few co-morbid conditions receiving dose reduced chemotherapy experienced acceptable toxic effects; a partial response was documented in 10 out of 50 pts.
  • The expanding use of chemotherapy and target therapy in this clinical setting has profound influence on health care management and costs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961580.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ferrari S, Rovati B, Collovà E, Grasso D, Sagrada P, Porta C, Riccardi A, Danova M: Impact of chemotherapy (CT) on ex-vivo generation of dendritic cells (DCs) in advanced breast cancer (ABC) patients (pts). J Clin Oncol; 2004 Jul 15;22(14_suppl):2583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of chemotherapy (CT) on ex-vivo generation of dendritic cells (DCs) in advanced breast cancer (ABC) patients (pts).
  • : 2583 Background Among the several problems in planning and carrying out clinical trials with ex-vivo-generated, tumor antigen-loaded DCs for solid tumors, the pts selection, the optimal time to take blood for generating DCs and the impact on them of number and types of previous CT could also play a role.
  • To date, high quantity of DCs can be generated after high-dose CT plus G-CSF in both BC and NHL pts.
  • Patients and Methods Sixteen pts, aged 56 (range 43- 65), were studied 1 to 3 month after an objective response was obtained with a 1<sup>st</sup>-line CT (Epirubicin+Docetaxel combination at standard dosages, without the scheduled utilization of G-CSF) for their metastatic disease.
  • DCs were generated from 25 ml of blood and following the standard procedure; the monocyte selection was performed with anti-CD14 microbeads (Miltenyi), followed by an immunomagnetic separation (MiniMacs, Miltenyi).
  • This indicate that besides clinical and biological characteristics, a potentially negative effect of the currently employed CT drugs on the phenomenon of ex vivo generation of DCs has to be taken into account when clinical trials are planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015285.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Rao RA, Chin K, Pilichowska M, Foss F: Outcomes in peripheral T-cell lymphoma: Prognosis based on IPI staging. J Clin Oncol; 2004 Jul 15;22(14_suppl):6706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in peripheral T-cell lymphoma: Prognosis based on IPI staging.
  • : 6706 Background: The T cell non-Hodgkin's lymphomas comprise a heterogeneous group of diseases which, with the exception of anaplastic large cell lymphoma, are associated with short response durations and survival after conventional cytotoxic chemotherapy .
  • Recently, a retrospective review by the Non-Hodgkin's Lymphoma Classification Project demonstrated that survival and failure-free survival were correlated with performance status and the International Prognostic Index (IPI).
  • METHODS: We performed a retrospective analysis of 35 patients (m=20, f=15) with non-cutaneous T-cell lymphoma treated at a single institution to determine whether clinical features or IPI classification were predictive of outcome.
  • The histopathologic subtypes included: AILD (5), NK-T cell lymphoma (2), PTCLu (14), HTLV-1 associated ATL (3), T-CLL (6), T-ALL (5).
  • The majority of patients had advanced disease (31 stage IV, 3 Stage III) at presentation.
  • The majority of patients (68%) were treated with anthracycline based multi-agent chemotherapy.
  • Further multi-institutional studies are warranted to further explore the predictors of outcome in underrepresented histologic subtypes of T-cell NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ramanarayanan J, Hernandez-Ilizaliturri FJ, Czuczman MS: Oblimersen sodium (G3139) targeting bcl-2 mRNA overcomes acquired resistance to rituximab and sensitizes rituximab-resistant non-Hodgkin's lymphoma (NHL) cells to rituximab-associated complement mediated cytotoxicity (CMC) and antibody dependant cellular cytotoxicity (ADCC). J Clin Oncol; 2004 Jul 15;22(14_suppl):3180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen sodium (G3139) targeting bcl-2 mRNA overcomes acquired resistance to rituximab and sensitizes rituximab-resistant non-Hodgkin's lymphoma (NHL) cells to rituximab-associated complement mediated cytotoxicity (CMC) and antibody dependant cellular cytotoxicity (ADCC).
  • : 3180 Background: Bcl-2 overexpression is associated with chemoresistance and poor outcome in large cell lymphoma.
  • Targeting Bcl-2 expression in rituximab-resistant cell lines (RRCL) is a potential strategy to overcome acquired antibody resistance.
  • Exposure of 2R to G3139 for 48 hours prior to rituximab therapy lead to a significant increase CMC [mean % lysis 55.89%, 95%C.I.: 42.1-65.9%] [P= 0.010].
  • CONCLUSIONS: The correlation of Bcl-2 overexpression with rituximab-resistance suggests that shared pathways of resistance may exist between biological and chemotherapy agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014916.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Rule S, Smith P, Qian W, Gambell J, Curtis N, Johnson P, Linch D: Application of the mantle international prognostic index (MIPI) to patients with mantle cell lymphoma treated with fludarabine/cyclophosphamide: Results from a UK NCRI Lymphoma Group study. J Clin Oncol; 2009 May 20;27(15_suppl):8555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of the mantle international prognostic index (MIPI) to patients with mantle cell lymphoma treated with fludarabine/cyclophosphamide: Results from a UK NCRI Lymphoma Group study.
  • : 8555 Background: Mantle cell lymphoma (MCL) remains an incurable malignancy with conventional chemotherapeutic options with little randomised evidence to help direct therapy.
  • The International Prognostic Index (IPI) for diffuse large cell lymphoma or Follicular Lymphoma International Prognostic Index (FLIPI) showed poor separation of survival curves in MCL patients.
  • A new prognostic index (MIPI) based on age, performance status, lactate dehydrogenase (LDH), and leukocyte count was developed for patients with advanced stage MCL.
  • Data from a randomised phase II NCRI trial designed to assess the effect of adding rituximab to an all oral chemotherapy regimen has been used to validate the MIPI.
  • Patients could receive up to 8 cycles of treatment but no consolidation therapy was permitted.
  • The primary outcome measures were response rate and the feasibility of a phase III randomised study.
  • Median age 64 (36-88) with a significant male predominance.
  • CONCLUSIONS: This large study of patients treated with an oral purine analogue combination confirms that the MIPI is predictive for OS.
  • However MIPI does not discriminate for PFS suggesting that those patients with high scores have an inferior response to subsequent therapy post relapse after FC based therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960988.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Noga SJ, Mo M, Dreiling L, Ozer H: Are comorbidities present in non-Hodgkin's lymphoma (NHL) patients (pts) enrolled in recent clinical trials different from those observed in previous clinical trials? J Clin Oncol; 2009 May 20;27(15_suppl):e19540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are comorbidities present in non-Hodgkin's lymphoma (NHL) patients (pts) enrolled in recent clinical trials different from those observed in previous clinical trials?
  • As NHL treatments have changed and NHL rates in the US have increased 81% from 1973 to 1997 (Garber 2001), pt characteristics of NHL practice-changing studies may have changed to reflect the general NHL population.
  • Here we summarize major co-morbid conditions present in pts from 4 key NHL trials published from 1976 to 2007.
  • METHODS: Intermediate/high-grade NHLs are sensitive to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; McKelvey 1974; Fisher 1993), especially when combined with rituximab (RCHOP; Coiffier 2002).
  • Entry criteria and demographics were tabulated from 4 interventional NHL trials published from 1976 to 2007: McKelvey 1976, a randomized study of 420 pts comparing CHOP and HOP; Fisher 1993, a phase 3, randomized study of 899 pts comparing CHOP, m-BACOD, ProMACE-CytaBOM, and MACOP-B; Coiffier 2002, a randomized study of 399 pts comparing CHOP with RCHOP; Noga 2007, an open-label study that included 325 NHL pts in community practice.
  • RESULTS: More recent NHL trials enrolled older pts compared with earlier trials ( Table ).
  • CONCLUSIONS: More recent clinical trials tend to enroll older pts compared with earlier trials and tend to include pts with the major co-morbidities often seen in the general NHL population.
  • Physicians may be more aware that cancer pts often have a significant prevalence of co-morbid conditions and that supportive care may allow these pts to benefit from study treatment.
  • Clinical practice may also be changing to allow more elderly pts with co-morbidities to receive aggressive chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960999.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Sola CB, Silva L, Saliba R, De Lima M, Giralt S, Qazilbash M, Champlin R, Khouri I, Popat U, Hosing C: Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization.
  • : 7040 Background: Patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) who fail to mobilize adequate peripheral blood stem cells (PBSC) often undergo bone marrow (BM) harvest for autologous transplantation.
  • METHODS: In this retrospective study (May 1996-September 2006), we identified 36 out of a total of 750 pts with advanced NHL, who failed to collect adequate PBSC and subsequently underwent BM harvest followed by ABMT.
  • Decision to harvest BM was left to the treating clinician.
  • Histology was intermediate grade in 31 (86%) patients and low grade in 5 (14%).
  • Twelve pts (35%) had history of BM involvement with lymphoma.
  • Median number of chemotherapy cycles received prior to mobilization was 3 (range 1-6).
  • At the time of stem cell mobilization 18 (50%) were in complete remission (CR), 13 (37%) were in partial remission (PR) and 5 (13%) had progressive disease (PD).
  • RESULTS: The median total nucleated cell dose and CD34+ cell dose harvested/kg were 3.72 x 10<sup>8</sup> (range 0.25-58.0) and 1.6 x 10<sup>6</sup> (range 0.03-5.8), respectively.
  • After ABMT, 33 of 35 evaluable (94%) pts engrafted neutrophils with median time to ANC 0.5 x 10<sup>9</sup>/L of 23 days (range 8-47).
  • Median time to platelet count 20 x 10<sup>9</sup>/L was 63 days (range 11-375).
  • CONCLUSIONS: ABMT is feasible in pts who fail to mobilize adequate PBSC, however, these pts have longer time to engraftment.
  • Non-myeloablative allogeneic transplantation may provide better outcomes with similar toxicity and needs to be further studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Cunningham D, Smith P, Mouncey P, Qian W, Pocock C, Ardeshna KM, Radford J, Davies J, McMillan A, Linch D: A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma.
  • : 8506 Background: The addition of rituximab to standard therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP21) has resulted in improved survival outcomes in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL).
  • In addition, the administration of CHOP as a 14 day cycle (CHOP14) has shown benefit over standard CHOP21 chemotherapy.
  • This randomised study was designed to evaluate the toxicity and survival outcomes achieved with the addition of rituximab to CHOP14 (R-CHOP14), as compared to standard therapy (R-CHOP21) in newly diagnosed DLBC NHL.
  • Patient characteristics in the R-CHOP21 and R-CHOP14 arms are; IPI score of ≥4 17%:15%, stage III/IV disease 63%:62%, B symptoms 44%:47%, bulk disease 51%:48%.
  • 82% of patients in the R-CHOP21 arm completed study therapy as compared to 89% in the R-CHOP14 arm.
  • Reported grade III/IV toxicities in the R-CHOP21 and R-CHOP14 arms are; neutropenia 57%:31%, thrombocytopenia 5%:9%, Infection 22%:17%, cardiac 1%:2%, nausea & vomiting 8%:8%, mucositis 2%:3%.
  • The radiological complete response rate (CR/CRu) is 47% in both treatment arms.
  • With a median follow-up 14 months 805 patients remain alive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960856.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Srinivas S, Cholankeril M, Chang VT, Morales-Muyuela E, Duque L, Toomey K, Kasimis B: Non-Hodgkin's lymphoma (NHL) patients at a VA medical center: Comorbidity and treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e19559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma (NHL) patients at a VA medical center: Comorbidity and treatment.
  • : e19559 Background: We hypothesized that measures of comorbidity may help explain the number of treatments administered to patients with non-Hodgkin's lymphoma.
  • METHODS: We performed a retrospective, IRB approved protocol, using chart review of all patients diagnosed with non-Hodgkin's lymphoma at the VANJHCS from January 1, 1997 through December 31, 2008.
  • Records were reviewed for demographic, clinical, pathological data, the number of chemotherapy regimens, radiation therapy, and total number of treatments and survival.
  • We tabulated the Charlson Comorbidity Index (CMI), the Kaplan-Feinstein Comorbidity Index (KFI), the Cumulative Illness Rating Scale (CIRS), International Prognostic Index (IPI), and performance status (PS) were tabulated for 100 patients seen at a VA Medical Center.
  • There were 61 deaths (61%) with M survival(MS) 1068 days(13-3976).
  • The M total number of systemic therapy regimens received was 1(0-4.5), M radiotherapy was 0(0-1) and the overall M total treatment regimens used was 1 (0-4.5).
  • IPI was a significant predictor in the use of radiation therapy (p<0.054) but did not correlate with the use systemic therapy.
  • The CMI was a predictor of the use of systemic chemotherapy (p<0.007), and the total number of treatments received (p<0.011), but not the KFI or the CIRS 17.
  • The performance status did not predict for the number of treatments.
  • In a Cox regression analysis, the number of treatments did not affect survival.
  • CONCLUSIONS: This data provides evidence that one measure of comorbidity, the CMI, may partially explain the number of systemic therapy treatments, and total treatments received by NHL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961077.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Levine AM, Quinn DI, Gorospe G, Lenz HJ, Tulpule A: Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies. J Clin Oncol; 2004 Jul 15;22(14_suppl):3008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel VEGF-antisense coumpound (VEGF-AS, Veglin) has been developed, targeting VEGF-A,-C and -D.
  • All failed standard therapy including systemic chemotherapy in 24 (92%), biologics/ immunotherapy in 13 (50%), and radiation in 9 (35%).
  • The most common tumor types accrued were lymphoma (NHL) in 5; sarcoma in 4; renal and AIDS-related Kaposi's sarcoma in 3 each; colon and lung in 2 each.
  • Plasma VEGF levels declined in 56% of pts.Veglin infusions were well tolerated with no dose limiting toxicities observed at doses up to 85 mg/m<sup>2</sup>.
  • One case of grade 3 anemia has occurred; there was no grade 3 or 4 neutropenia or thrombocytopenia.
  • Non-hematologic side effects were grade 1 or 2 and included fatigue, hypotension, and perioral numbness (all <20% of pts).
  • [Formula: see text]: There has been anti-tumor activity in 2 patients with AIDS-related KS (one biopsy-proven CR at level 1), in 1 pt with renal cell (PR), and 1 pt with tumor cutaneous T-cell NHL (PR).
  • CONCLUSIONS: Veglin is well tolerated at doses up to 85 mg/m<sup>2</sup>with no dose limiting toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Maraj I, Hernandez-Ilizaliturri FJ, Chisti M, Czuczman MS: Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):8576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib.
  • : 8576 Deacetylases (DACs) are enzymes that remove the acetyl groups from target proteins [histones (class I) and non-histones (class II)], leading to regulation of gene transcription and other cellular processes.
  • In order to develop therapeutic options for refractory/resistant B-cell lymphomas we studied the effects of LBH589 in the anti-tumor activity of chemotherapy agents and monoclonal antibodies in a panel of rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), and in lymphoma cells isolated from patients with treatment-naïve or refractory/relapsed B-cell lymphomas by negative selection using magnetic beads.
  • NHL cells lines were exposed to the following chemotherapy agents or monoclonal antibodies: CDDP, doxorubicin, vincristine, bortezomib or rituximab, veltuzumab, or isotype, alone or in combination with LBH589.
  • In dose-sequence studies the treatment with LBH589 preceded or followed in vitro exposure to the chemotherapy agent or the monoclonal antibody by 24 hrs.
  • Changes in ATP content were determined by cell titer glow assay.
  • RNA was isolated from NHL cell lines exposed to LBH859 and changes in gene expression of the Bcl-2 family members were determined by qualitative polymerase chain reaction (PCR).
  • Synergistic activity was observed by combining LBH589 and chemotherapy agents, bortezomib or either of the two anti-CD20 mAbs studied.
  • Findings suggest that LBH589 added to systemic anti-CD20 and/or chemotherapy could result in a novel and potent treatment strategy against B-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Reiter A, Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Mann G, Schrappe M: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):10000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL).
  • : 10000 Background: Pediatric mature B-cell NHL differ from aggressive B-NHL of adults in terms of biology and treatment outcome.
  • In contrast to adults, rituximab (Rx) is not established in the treatment of pediatric B-NHL has not be determined yet.
  • Even the activity of Rx in pediatric B-NHL is not determined.
  • We conducted a phase II window study to examine the activity of Rx in newly diagnosed pediatric B-NHL.
  • METHODS: Eligibility: age < 19 y, CD20 + B-NHL, ≥ 1 measurable lesion/s, informed consent.
  • Exclusion: Lansky performance scale 5, pre-treatment, impaired renal-, heart-, liver-function, hepatitis B, pre-existing disease, pregnancy.
  • TREATMENT: Rx 375 mg/m<sup>2</sup> IV at day 1; concomitant therapy: Rasburicase, steroids only for anaphylaxis, intrathecal (IT) triple drug at days 1, 3 for CNS+ pts only.
  • Begin of chemotherapy at day 5.
  • Forty-nine pts were not evaluable for response: Withdrawal (anaphylaxis 8, ATL 2, suspected progression, not verified 4, other 2), IT therapy in CNS- pts (8), corticosteroids (3), technical inadequacy of response evaluation (21), no index lesion (1).
  • RR by histology: BL/B-ALL 29/68, DLBCL 6/14, juvenile follicular lymphoma 1/2, PMBCL 1/1, B-NHL nfs 0/2.
  • Fifty pts were non-RPs.
  • CONCLUSIONS: Although the RR was lower than requested Rx as single agent is active in pediatric B-NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Ghielmini ME, Hsu Schmitz S, Martinelli G, Peccatori F, Hess U, Fey M, Zucca E, Stahel R, Ketterer N, Cerny T: Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. J Clin Oncol; 2009 May 20;27(15_suppl):8512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98.
  • : 8512 Background: In FL, rituximab as a single agent obtains a response rate of 50-70% with an EFS of 1-3 years depending on the population studied.
  • Some patients respond to this treatment for a prolonged time, so we investigated, in a clinical trial, the proportion of long-term responders and the characteristics predicting long-term response.
  • METHODS: Between 1998 and 2002, chemotherapy naïve (n = 64) or pre-treated (n = 138) FL patients received 4 weekly doses of rituximab: those responding or with stable disease were randomized to either no further treatment (observation, n = 78) or 4 additional doses of rituximab given at 2 months intervals (consolidation, n = 73).
  • RESULTS: At a median follow up of 8.9 years, and with all living patients having been followed for at least 5 years, the median event-free survival (EFS: time until progression, relapse, second tumor or death) is 13 months for the observation and 24 months for the consolidation arm (p=0.0012).
  • The only significant prognostic factor for EFS in a multivariate Cox regression was having received consolidation rituximab (hazard ratio = 0.58, CI = 0.44-0.87, p = 0.008), whereas being chemotherapy naïve, presenting with stage < IV and showing a VV phenotype at position 158 of the Fc receptor RIIIA were not any more significantly prognostic in this long term analysis, in contrast to previous data with shorter follow-up.
  • No long-term toxicity from treatment was observed.
  • CONCLUSIONS: It appears that the EFS advantage of prolonged versus short course rituximab continues for many years after the end of treatment.
  • This seems to hold true independently from previous treatment, stage or 158-phenotype of the Fc receptor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Mena RR, Smith J, George S, Geils G, Geils G, Yunus F: Safety and efficacy of pentostatin and rituximab in patients with low-grade B-cell non-Hodgkin's lymphoma, including chronic lymphocytic leukemia (Protocol N007). J Clin Oncol; 2004 Jul 15;22(14_suppl):6569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of pentostatin and rituximab in patients with low-grade B-cell non-Hodgkin's lymphoma, including chronic lymphocytic leukemia (Protocol N007).
  • : 6569 Background: Chemotherapy for patients with low grade B-cell malignancies is seldom curative.
  • Therapies that delay disease progression with limited toxicity may benefit patients considerably.
  • Pentostatin and rituximab have demonstrated activity and safety in single agent and combination therapies against B-cell NHL and CLL.
  • The present study evaluates the safety and efficacy of pentostatin and rituximab in previously treated and untreated patients with low grade NHL and CLL Methods: 143 patients with NHL (N=77) and CLL (N=66) were enrolled in this study.
  • Disease response was evaluated between days 57-64 according to the International Working Group criteria for NHL.
  • Patients with PR or SD, could repeat treatment days 8 through 50, at investigators discretion.
  • Safety and time to progression were assessed.
  • OR rate was 70.3% in NHL (N=64) and 43.8% in CLL patients (N=48).
  • Among patients with chemotherapy prior to study, OR rate was 56.6% in NHL (20% CR, 13.3% CRu, 23.3% PR, N=30) and 33.3% in CLL patients (3.7% CR, 3.7% CRu, 25.9 PR, N=27).
  • In patients with no prior chemotherapy, OR rate was 82.3% in NHL (35.3% CR, 8.8% CRu, 38.2 PR, N=34) and 57.1% (14.3% CR, 9.5% CRu, 33.3 PR, N=21) in CLL patients.
  • Grade 3-4 adverse events occurred in 42.7% of intent-to-treat patients.
  • The most frequently observed grade 3-4 adverse events were pneumonia (7.7%), neutropenia (6.3%), fever (3.5%), rash (3.5%), and shortness of breath (3.5%).
  • One patient expired on treatment from causes unrelated to study medications.
  • CONCLUSIONS: Preliminary results suggest that in patients with low grade NHL and CLL, combination chemotherapy with pentostatin and rituximab appears well tolerated and effective.
  • Observed grade 3-4 toxicities were similar to pentostatin and rituximab used as single agents.
  • Preliminary results on time to progression will be reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Juweid ME, Wiseman G, Menda Y, Wooldridge J, Link BK, Stolpen A, Graham MM, Vose JM: Integrated PET based response classification for non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated PET based response classification for non-Hodgkin's lymphoma (NHL).
  • : 6533 Background: FDG-PET is increasingly being utilized for response assessment of NHL.
  • The purpose of this study was to determine whether FDG-PET+CT result in a more accurate response classification compared with CT alone in patients with NHL.
  • METHODS: FDG-PET and CT were performed in 54 aggressive NHL patients 1-3 months following 4-8 cycles of CHOP-based chemotherapy.
  • CONCLUSIONS: Compared with CT-, PET+CT-based response designations more accurately reflect expected outcome in aggressive NHL.
  • These results challenge the current paradigm in response assessment of patients with NHL and suggest that PET/CT-based response classification may become the new standard for NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016941.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Waters J, Chau I, Norman AR, Pollard M, Wotherspoon A, Cunningham D: Gemcitabine (GEM), cisplatin (P) and methylprednisolone: A salvage regimen in relapsed Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine (GEM), cisplatin (P) and methylprednisolone: A salvage regimen in relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • : 6589 Background: Relapsed HD and NHL remain a therapeutic challenge.
  • Non-cross resistant therapy incorporating P is a standard approach, but the optimal regimen has not been defined.
  • GEM, a novel nucleoside analogue has shown limited single agent activity in heavily pre-treated lymphomas.
  • METHODS: Patients (pts) had relapsed HD or NHL, received at least 1 prior chemotherapy regimen, performance status 0-2, adequate organ function.
  • Prior treatment with P or GEM was not permitted.
  • Pts with HIV-related lymphoma were excluded.
  • Treatment was repeated every 28 days for up to 6 cycles.
  • Pt characteristics: median age 41 yrs (range 17-68); M/F 29/13; PS 0/1/2: 13/23/5; histology: diffuse large B-cell NHL 11, T-cell NHL 6, other NHL 7, HD 18; stage I/II/III/IV: 1/10/12/19; IPI 0/1/2/3/4: 5/17/11/8/1; number of prior treatment regimens 1/2/3/>3: 18/12/3/9.
  • 18 pts relapsed within 90 days of last chemotherapy.
  • Median time to disease progression is 6.2 months and median overall survival 25.8 months.
  • Grade 3/4 toxicity: leucopenia (50% of pts), neutropenia (63%), thrombocytopenia (20%), anaemia (7%).
  • There was no grade 4 non-haematological toxicity.
  • Grade 3 toxicity: nausea and vomiting (3%), diarrhoea (3%), alopecia (3%).
  • Grade 1 and 2 neurological toxicity occurred in 40% and 6% of pts respectively.
  • CONCLUSIONS: GEM-P is an active and feasible salvage regimen in relapsed and refractory HD and NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Krzyzanowska MK, Treacy JT, Maloney BA, Lavino A, Jacobson JO: Development of a registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center. J Clin Oncol; 2004 Jul 15;22(14_suppl):6062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center.
  • : 6062 Background: While most chemotherapy (CT) administration occurs in routine care settings, there is a lack of data on toxicity (TOX) outside of clinical trials.
  • After developing a mechanism for identifying all patients with CT-related hospitalizations in our center we created a prospective registry of such admissions in order to examine trends in TOX, modify practice, and establish benchmarks for severe TOX in a community cancer center.
  • METHODS: The North Shore Cancer Center is a community-based cancer facility in Peabody, MA.
  • Each admission was reviewed by a panel of hospital staff to determine whether it was treatment-related; admission information was collected using a standard form.
  • During this time period 7,632 patient months of parenteral CT were administered.
  • The median time from last CT administration to admission was 7 d.
  • NHL (25%) and colorectal cancer (17%) were the most frequent diagnoses.
  • The mean length of stay was 7.3 d (range 0-49); 6 patients died during hospitalization (5%).
  • When the registry was reviewed to identify areas where care may be improved, several admissions for decadron-related hyperglycemia in non-diabetic patients with myeloma were identified.
  • CONCLUSIONS: About one third of hospital admissions in patients receiving CT are treatment-related and most occur in patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014967.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Richey EA, Carson KR, Evens AM, Focosi D, Bennett CL: "Beating the bushes" to identify previously unreported cases of a rare and potentially fatal adverse drug reaction: Comparison of HIV-negative rituximab-associated progressive multifocal leucoencephalopathy (PML) cases obtained by the Research on Adverse Drug Events and Report (RADAR), the FDA, the manufacturer, and a literature review. J Clin Oncol; 2009 May 20;27(15_suppl):6604

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Beating the bushes" to identify previously unreported cases of a rare and potentially fatal adverse drug reaction: Comparison of HIV-negative rituximab-associated progressive multifocal leucoencephalopathy (PML) cases obtained by the Research on Adverse Drug Events and Report (RADAR), the FDA, the manufacturer, and a literature review.
  • Potential risk factors for PML include chemotherapy, corticosteroids, and HIV-infection.
  • In an independent pharmacovigilance effort, RADAR queried clinicians at academic lymphoma referral centers regarding possible unreported cases of R-associated PML.
  • METHODS: RADAR surveyed clinical lymphoma experts at 13 major academic centers and identified 21 previously unreported cases of R-associated PML.
  • The estimated incidence is 1 PML case per 4,700 R-treated NHL patients (based on the number of cases in this report, manufacturer estimates of 1,560,000 total global R exposures, and an estimate of six R doses per patient).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Emmanouilides C, Czuczman MS, Revell S, Witzig TE, Wang H, Gordon LI, Skikne B, Foster P, Molina A: Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan. J Clin Oncol; 2004 Jul 15;22(14_suppl):6696

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan.
  • Since tMDS/tAML has been associated with prior exposure to chemotherapy and radiation, we determined the incidence of tMDS/tAML in pts treated with ibritumomab tiuxetan from 4 registrational trials that have long-term follow-up.
  • These pts had received a median of 2 (range 1 - 9) prior treatments.
  • With a median follow-up of 38 mos (range 1.2 - 75.5 mos), 7 pts (3.3%) have developed tMDS/tAML.
  • Diagnosis of tMDS/tAML occurred 8 to 50 mos (median 18 mos) following therapy and 4.3 to 14 yrs (median 8 yrs) following the diagnosis of lymphoma.
  • The annualized rates for the development of tMDS/tAML were 0.34% and 0.70% per yr from initial NHL diagnosis and from ibritumomab tiuxetan treatment date, respectively.
  • This compares favorably to the published risk of tMDS/tAML in treated NHL pts of 1-1.5%/yr from 2 -10 yrs after initiation of therapy.
  • Chromosome 5 and/or 7 abnormalities and/or deletions were detected in most pts, suggesting an association with prior alkylator-based therapy.
  • Two of these cases had documented abnormal baseline BM cytogenetic abnormalities prior to treatment with ibritumomab tiuxetan.
  • CONCLUSIONS: Ongoing follow-up of pts from our registrational trials suggests that the annualized incidence of tMDS/tAML is consistent with that expected from this population of heavily treated NHL patients and does not appear to be increased following RIT with the ibritumomab tiuxetan therapeutic regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014380.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA: Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL).
  • : 6581 Background: Proteasome inhibition disrupts many cell cycle checkpoints and pathways that lead to apoptosis.
  • Preclinical and ph 1 studies suggested the proteasome inhibitor bortezomib (VELCADE<sup>™</sup>, Vc) was active in lymphoma.
  • METHODS: The primary objective of this ph 2 study was to document the response rate (RR) and toxicity of Vc in pts with relapsed or refractory NHL.
  • Pts ≥ 16 yr, with relapsed or refractory mantle cell (MCL, gp A) or other B cell lymphomas (gp B) were eligible.
  • There were 25 pts in gp A and 20 pts in gp B, including 10 diffuse large cell lymphoma (DLCL), 4 follicular lymphoma (FL), 3 transformed (t) FL, 2 small lymphocytic lymphoma (SLL), 1 Waldenström's macroglobulinemia (WM).
  • Gp A had 3 median prior therapies (range 1-6); gp B had 4 (range 1-12).
  • In gp B, there were 8 ev DLCL with 1 PR (DOR 4 mo), 1 NC, 6 POD; 4 ev FL with 2 MR, 1 NC, 1 POD; 1 ev tFL with POD; 2 ev SLL with 1 NC, 1 POD; 1 WM pt had PR.
  • Grade 3/4 toxicities were GI (5 pts), hypotension/fatigue (6 pts), neuropathy (1 pt with prior vinca/taxanes), and pneumonia (2 pts); hematologic toxicities were neutropenia (8) (only 1 pt with ANC <500) and thrombocytopenia (14 pt) (only 1 pt with platelets <10; most entered with platelets <30-50).
  • CONCLUSIONS: This study showed remarkable activity of Vc in MCL and encouraging results in other B cell lymphomas.
  • Future studies will include combinations of Vc with other chemotherapy and/or biological agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Caggiano V, Morrison VA, Fridman M, Delgado DJ: A model to predict delivery of reduced chemotherapy dose intensity in the first three cycles of treatment among patients with non-Hodgkin's lymphoma and breast cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):6100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A model to predict delivery of reduced chemotherapy dose intensity in the first three cycles of treatment among patients with non-Hodgkin's lymphoma and breast cancer.
  • : 6100 Background: Reduction of chemotherapy dose intensity is common among patients receiving treatment for non-Hodgkin's lymphoma (NHL) and breast cancer.
  • A recent publication suggests that neutropenia is a cause of dose modifications, and that maintaining chemotherapy dose intensity in the initial cycles may be associated with improved outcomes.
  • We evaluated possible risk factors associated with delivery of reduced chemotherapy dose intensity in the first 3 cycles of treatment among a sample of patients with NHL or breast cancer.
  • METHODS: A historical case series of 1617 patients (704 NHL and 913 early-stage breast cancer) who received initial chemotherapy at 16 community and academic oncology practices between 1991 and 1999 were studied.
  • Reduced average relative dose intensity (ARDI) was defined as at least a 20% or 15% reduction in dose intensity for NHL and breast cancer patients, respectively.
  • Stepwise logistic regression was used to select risk factors significantly associated with a reduction in ARDI.
  • RESULTS: 427 of 1617 patients (26%) received reduced ARDI within the first 3 cycles of chemotherapy.
  • Patients with NHL were less likely to have a reduction in ARDI (OR 0.6; 95% CI 0.4-0.8).
  • CONCLUSIONS: Increased age, comorbidity (heart, renal or hepatic), low body surface area, and no preemptive growth factor in cycle 1 were associated with increased risk for delivery of reduced chemotherapy dose intensity in cycles 1 through 3 after controlling for differences in diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Schilling MB, Parks C, Deeter RG: Costs and outcomes associated with febrile neutropenia-related hospitalizations across patients with varying cancer types: A retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Costs and outcomes associated with febrile neutropenia-related hospitalizations across patients with varying cancer types: A retrospective analysis.
  • : e20560 Background: Neutropenia, the major dose-limiting toxicity of chemotherapy, is a frequent, often serious, and sometimes fatal complication of myelosuppressive chemotherapy.
  • Its economic and clinical impact is often under-appreciated, and thus this study evaluates the contribution of febrile neutropenia (FN) by tumor type as related to healthcare cost and mortality.
  • Unadjusted mean healthcare cost of hospitalization, length of hospital stay (LOS), and mortality rates were calculated, stratifying by cancer type (breast, metastatic breast, and lung cancers, non-Hodgkin lymphoma (NHL), or other hematologic tumors).
  • RESULTS: Among 598 hospitalized patients (mean age 63 years; 53% female) with cancer experiencing FN, the mean cost of hospitalization, LOS and mortality varied significantly by tumor type ( Table ).
  • Considerable variations exist across cancer types for hospitalization costs, LOS and mortality.
  • The tumor type is important in assessing the economic and clinical impact of FN hospitalizations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961149.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Ogura M, Kagami Y, Itoh K, Tobinai K, Chou T, Aikawa K, Ishizuka N, Hotta T, Shimoyama M, members of the Lymphoma Study Group of Japan Clinical Oncology Group (JCOG-LSG): Standard CHOP therapy for low (L) or low-intermediate (L-I) risk patients (pts) with aggressive non-Hodgkin's lymphoma (NHL): A multicenter phase II study by Japan Clinical Oncology Group (JCOG 9508). J Clin Oncol; 2004 Jul 15;22(14_suppl):6703

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standard CHOP therapy for low (L) or low-intermediate (L-I) risk patients (pts) with aggressive non-Hodgkin's lymphoma (NHL): A multicenter phase II study by Japan Clinical Oncology Group (JCOG 9508).
  • : 6703 Background: To confirm the efficacy and safety of standard CHOP therapy in Japanese pts with L or L-I risk aggressive NHL, we conducted a multicenter phase II study with overall survival (OS) as primary endpoint.
  • METHODS: Eligibility criteria were as follows: newly-diagnosed, intermediate or high grade NHL by Working Formulation; L or L-I risk by International Prognostic Index (IPI); clinical stage of II, III, IV or bulky I; ages less than 70; PS 0-3.
  • Eight courses of standard CHOP therapy were given every 3 weeks.
  • Involved-field radiotherapy (30 to 40 Gy) was added after chemotherapy for bulky disease at baseline, and was optional for residual tumors.
  • RESULTS: Between June 1995 and May 1999, a total of 213 pts were enrolled, and 173 pts were pathologically eligible (diffuse large B; 68%) by the central review according to WHO classification.
  • Major toxicity by JCOG toxicity criteria in all treated pts (212 pts) was grade 4 neutropenia (64%).
  • Non-hematologic toxicities were acceptable; the most frequent grade 3 toxicity was nausea/vomiting (3%), and grade 4 toxicity was observed in one who developed paralytic ileus.
  • One treatment-related death was observed due to hepatitis B virus reactivation.
  • CONCLUSIONS: CHOP was confirmed to be a standard therapy in Japanese pts with L or L-I risk aggressive NHL.
  • However, the relatively low %PFS suggests the necessity of further investigations to find more effective first-line therapy for L-I risk pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014620.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Keilholz U, Busse A, Schmittel A, Hütter G, Siehl J, Thiel E: A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high-grade non-Hodgkin's lymphoma and cardiac risk factors. J Clin Oncol; 2004 Jul 15;22(14_suppl):6708

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high-grade non-Hodgkin's lymphoma and cardiac risk factors.
  • : 6708 Background: CHOP is the standard combination chemotherapy for high-grade Non-Hodgkin's-lymphoma (NHL).
  • We performed a phase I/II study of a modified CHOP regimen including pegliposomal doxorubicin, termed CLAOP, in patients with high-grade NHL and cardiac risk factors.
  • RESULTS: 113 treatment cycles were administered to 22 patients.
  • In the initial 12 patients CLAOP21/20mg/m2 was well tolerated with a degree of hematotoxicity similar to that reported with regular CHOP.
  • The dose-dense CLAOP14/20mg/m2 was not associated with dose-limiting hematotoxicity, but three febrile episodes occurred in 27 treatment cycles.
  • Grade III leucopenia and febrile infections developed in 3 of 5 patients, and PPE grade III in 2 of 5 patients, respectively.
  • CONCLUSIONS: The recommended dose of pegliposomal doxorubicin in the CLAOP regimen for Phase II/III testing is 20mg/m2.
  • This regimen can be administered to lymphoma patients with concomitant cardiovascular disease without apparent cardiotoxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Dale DC, Crawford J, Agboola O, Lyman GH, Anc Study Group: Febrile neutropenia and reduced dose intensity in patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP and CNOP. J Clin Oncol; 2004 Jul 15;22(14_suppl):6599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile neutropenia and reduced dose intensity in patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP and CNOP.
  • : 6599 Background: Myelosuppression remains the major dose-limiting toxicity of systemic chemotherapy in patients with intermediate grade NHL.
  • METHODS: A survey of 1243 community oncology practices including nearly 5500 patients receiving chemotherapy for NHL was undertaken to evaluate the impact of demographic, clinical and treatment related factors on delivered dose intensity.
  • Relative dose intensity (RDI) was estimated for each drug as the ratio of dose intensity received to standard dose intensity for each regimen.
  • RESULTS: This analysis is limited to 3536 patients with aggressive NHL (Working Formulation D-H) treated with CHOP (87%) or CNOP (13%) chemotherapy over a 10-year period from 1992 to 2001.
  • Diffuse large cell histology was reported in 57%.
  • Febrile neutropenia (FN) occurred one or more times in 21% of patients of which 76% required hospitalization.
  • CONCLUSIONS: Nearly one-half of patients with aggressive NHL histology treated with CHOP-like regimens experienced substantial dose reductions related to age, stage, gender, obesity, regimen and previous FN hospitalization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016223.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Sierra J, Harms R, Mo M, Vogel CL: Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials.
  • : 9621 Background: Bone pain is the most commonly reported treatment-related adverse event (AE) associated with colony-stimulating growth factors.
  • METHODS: Completed Amgen-sponsored trials that both incorporated pegfilgrastim 6mg administered 24 hours after chemotherapy and utilized MedDRA library coding of AEs were examined.
  • The incidence of bone pain was determined by treatment (pegfilgrastim, filgrastim, or placebo), chemotherapy (taxane-containing or not), cycle, severity, age, and body surface area (BSA).
  • In studies comparing pegfilgrastim (n=74) and filgrastim (n==7) in pts with AML and NHL, 52% were female, and the mean (SD) age was 50 (15.1) years.
  • Similar proportions (CI) of pts reported bone pain (24.3% [16.1, 35.7] vs 25.4% [15.5, 37.5], respectively), and grade 3/4 bone pain was reported in 3% [0.3, 9] versus 0% [-, -] of pts, respectively.
  • CONCLUSIONS: Bone pain of any grade was commonly reported in all 3 groups (pegfilgrastim, filgrastim, and placebo) and was marginally higher in pts receiving pegfilgrastim compared with placebo.
  • Chemotherapy (eg, taxanes) may also contribute to bone pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Nademanee A, Forman SJ, Molina A, Kogut N, Fung HC, Yamauchi D, Anderson AL, Smith D, Liu AN, Raubitschek A: High-dose radioimmunotherapy with yttrium 90 (&lt;sup&gt;90&lt;/sup&gt;Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):6504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose radioimmunotherapy with yttrium 90 (<sup>90</sup>Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial.
  • RESULTS: Between 5/00 and 11/03, 31 patients (17 M: 14 F), median age 51 (range, 25-59.6) with follicular (n=9), diffuse large B-cell (n=17) and mantle cell (n=5) were treated.
  • All but two had received rituximab either alone (8), or in combination with chemotherapy (21).
  • The treatment was well tolerated with no transplant-related death.
  • All but one patient engrafted; median time to reach ANC > 500/μl and platelet > 20,000/μl was 10 days (range 8-17) and 19 days (range 12-123), respectively.
  • This novel preparative regimen is well tolerated and is effective in patients with refractory B-cell NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Chatal JF, Harousseau JL, Griesinger F, Meller J, Renner C, Kirsch CM, Naumann R, Kropp J, Wegener WA, Goldenberg DM: Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, &lt;sup&gt;90&lt;/sup&gt;Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. J Clin Oncol; 2004 Jul 15;22(14_suppl):2545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, <sup>90</sup>Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
  • : 2545 Background: A phase I/II, multi-center, dose-escalation trial was conducted to establish the safety, optimal dosing, and preliminary efficacy of <sup>90</sup>Y-epratuzumab administered weekly for 2 or 3 consecutive wks to pts with B-cell NHL who failed ≥1 regimen of standard chemotherapy.
  • Twenty-six pts with a median of 3 prior treatments have been treated, including 15 pts without prior bone marrow transplant (BMT) at 5-10 mCi/m<sup>2</sup>/wk (total <sup>90</sup>Y dose, 15-22.5 mCi/m<sup>2</sup>) and11 pts with prior BMT escalated separately at 2.5-5 mCi/m<sup>2</sup>/wk (total <sup>90</sup>Y dose, 5-10 mCi/m<sup>2</sup>).
  • RESULTS: Dose escalation is continuing, with no serious AEs considered treatment-related.
  • One pt in each escalation arm had protocol-defined DLT (>12 wk platelet recovery); otherwise, therapy was well tolerated with no significant toxicity besides transient hematologic depression, including 4 pts retreated without additional toxicity.
  • In 22 pts with treatment evaluations, 13 pts (59%) had an objective response (OR) by IWG criteria, including pts with and without BMT [5/9 (56%) and 8/13 (62%), respectively], with indolent and aggressive disease [8/10 (80%) and 5/12 (42%), respectively], across histologies [follicular NHL, 9/12 (75%); DLCL, 2/4 (50%); mantle cell, 2/6 (33%)], and in pts failing rituximab (9/15, 60%).
  • CONCLUSION: This study shows the feasibility and safety of a dose-fractionation schedule of a <sup>90</sup>Y-labeled anti-CD22 Mab, obtaining therapeutic responses across all pt groups, including durable complete responses, and achieving higher cumulative doses than other RAIT agents given as single doses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015227.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Morrison VA, Caggiano V, Fridman M, Delgado DJ: A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):8068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients.
  • : 8068 Background: Chemotherapy used to treat cancer may produce severe (absolute neutrophil count ≤250/mm<sup>3</sup>) or febrile neutropenia (SFN), which often results in fever, infection, and hospitalization.
  • This can lead to dose delays or reductions in subsequent chemotherapy cycles and/or early termination of therapy.
  • Recent studies suggest most patients who experience SFN do so early in the course of chemotherapy, in particular during the first cycle.
  • The ability to identify patients at risk for developing neutropenia early in their therapy might help guide appropriate hematopoietic growth factor use.
  • We evaluated possible risk factors associated with cycle 1 SFN among a sample of patients with NHL or breast cancer.
  • METHODS: A historical case series of 1,617 patients (704 NHL and 913 early-stage breast cancer) who received initial chemotherapy at 16 community and academic oncology practices between 1991 and 1999 were selected for study.
  • RESULTS: A total of 461 patients (29%) experienced at least one SFN episode; 268 (58%) of these patients (167 [59%] with NHL and 101 [56%] with breast cancer) had SFN in cycle 1.
  • Risk factors associated with cycle 1 SFN included age ≥65 years (Odds ratio [OR] 2.08; 95% CI: 1.48-2.92), baseline hemoglobin <12.0 g/dL (OR 1.90; 95% CI: 1.41-2.58), presence of heart, renal, or liver disease (OR 2.12; 95% CI: 1.03-4.36), NHL (OR 1.64; 95% CI: 1.16-2.32), planned full chemotherapy dose intensity (OR 2.74; 95% CI: 1.55-4.84), and no growth factor in the first 5 days of cycle 1 (OR 1.82; 95% CI 1.07-3.08).
  • In our model assessing chemotherapy-related SFN in breast cancer and lymphoma, patients ≥65 were twice as likely to have SFN in Cycle 1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015872.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Koc ON, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J: Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial of FavId. J Clin Oncol; 2004 Jul 15;22(14_suppl):2520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial of FavId.
  • : 2520 Background: Active immunotherapy of FL is a promising therapeutic strategy.
  • Anti-idiotype (Id) antibody and T-cell responses to Id-KLH have been correlated with responses in patients with FL.
  • In a phase II trial, we evaluated the efficacy of Id-KLH vaccination in patients with FL, after cytoreduction with rituximab and during B-lymphopenia.
  • METHODS: Pts with gr 1,2 FL who were treatment naïve; relapsed/refractory to chemo or relapsed after rituximab were eligible.
  • Prior trerapy (in 60 of 95) was chemo and rituximab (31) chemotherapy alone (23) or rituximab alone (6).
  • Robust T-cell responses to both Id and KLH were observed (3 of 3 pts).
  • Anti-KLH antibody responses were seen in 2 of 10 pts and were delayed until B-cell recovery.
  • CONCLUSIONS: Id-KLH induces immune responses even after rituximab mediated B-cell depletion in FL patients.
  • Preliminary data suggest that Id-KLH may prolong TTP after rituximab therapy and this strategy will be tested in a randomized phase III trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Singh T, Satheesh C, Ankit J, Sajeevan KV, Appaji L, Arunakumari B, Padma M, Mamatha HS: Use of Port-A-Cath in pediatric cancer patients: Experience from a tertiary cancer center in south India. J Clin Oncol; 2009 May 20;27(15_suppl):e20747

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Port-A-Cath in pediatric cancer patients: Experience from a tertiary cancer center in south India.
  • : e20747 Background: Implanted subcutaneous (s.c.) central venous port accesses including Port-A-Cath (PAC) facilitate the administration of chemotherapy or blood products and are frequently used in children with cancer.
  • Disease distribution included ALL(80%), AML(5%), NHL(5%), neuroblastoma (5%) and RMS (5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962033.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hoskin P, Czuczman MS: Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):8543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL).
  • : 8543 We found that repeated rituximab exposure leads to deregulation of Bcl-2 proteins and concomitant chemotherapy resistance.
  • We demonstrated that obatoclax (O), a potent Bcl-2 inhibitor, enhanced the anti-tumor activity of rituximab or chemotherapy agents.
  • In the current work we study the interactions between bortezomib (B) and O against B-cell NHL.
  • Studies were conducted in rituximab sensitive (RSCL) and resistant cell lines (RRCL), as well as in malignant B-cells derived from patients with NHL (n = 20).
  • Cell death was determined by the Cell glow luminescent assay and DNA synthesis by [<sup>3</sup>H]-Thymidine incorporation.
  • O or B monotherapy induced time- and dose-dependent cell death of all cells tested.
  • In vitro exposure of RRCL, RSCL and lymphoma specimens to O and B resulted in significant synergistic activity.
  • In vitro exposure of NHL cells to O lead to p53 degradation and Noxa or PUMA induction; while exposure to B resulted in Bax upregulation and Mcl-1 downregulation.
  • Inhibition of caspase activity did not affect the ability of O or B to kill NHL cells.
  • Additionally, cell death induced by O could be inhibited by knock-down of Beclin-1 or p53.
  • Our findings strongly suggest that O added to B may result in a novel and potent therapeutic strategy against aggressive NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Hentrich M, Gerl A, Lutz L, Karthaus M, Schiel X: Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):e19546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL).
  • : e19546 Background: Rituximab (R) is increasingly used for the treatment of B-NHL.
  • METHODS: The records of consecutive pts treated at 2 institutions from 01/06 to 12/08 with R-containing chemotherapy or R-maintenance therapy (R-M) for NHL were analyzed for severe UT and OI.
  • 7 of 99 pts (7%) (2 females, 5 males) with a median age of 69.5 yrs (range 41-76) experienced UT (n=4) or OI (n=3).
  • UT consisted of interstitial pneumonitis (IP) in 2 pts after 8 and 6 cycles of R-CHOP for diffuse large cell lymphoma (DLCL), a case of congestive heart failure (NYHA III°) after 6x R-CHOP + 2x R-M for follicular lymphoma (FL) and a case of grade 4 pancytopenia lasting for 22 days following 2x R-FC for chronic lymphocytic leukemia.
  • IP completely resolved after initiation of prednisone (n=1) or under empiric antimicrobial therapy (n=1).
  • Congestive heart failure improved under appropriate therapy and the pt received 2 more cycles of R-M.
  • Pancytopenia slowly recovered under therapy with G-CSF, R was terminated.
  • OI consisted of pneumocystis jirovecii pneumonia after 5x R-CHOP-14 for DLCL, Epstein-Barr-virus (EBV)-associated hepatitis after 5x R-CHOP-21 for relapsed FL and generalized herpes zoster following 6x R-bendamustine (RB) + 1x R-M for recurrent BALT-lymphoma.
  • Infections resolved under antimicrobial therapy.
  • Moreover, 2 pts were transferred to us for therapy of enterovirus-induced encephalitis after 6x R-CHOP-21 + 2x R-M for FL (n=1) and cerebral toxoplasmosis in a pt heavily pretreated with R-containing therapy for relapsed mantle cell lymphoma (n=1).
  • Awareness of UT/OI, rapid diagnostic proceedings and, whenever possible, initiation of therapy are essential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Petrakova K, Koukalová H, Soumarová R, Palácov' M, Blažkova S, Vyzula R: Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD). J Clin Oncol; 2004 Jul 15;22(14_suppl):6695

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD).
  • The most of published studies compare observed and expected numbers of cancers in the cohort with use of age-specific national incidence rate.
  • Aim of our study was quantification of RR of SM in patients treated by "risk" RT ± CT (mantel field for breast cancer, and thyroid cancer, upper abdomen for stomach cancer, inverted Y or total nodal irradiation for colon cancer, inverted Y for gynecologic cancer) in comparison with patients treated by CT ± "non risk" RT.
  • METHODS: 851 patients (475 men and 376 women) with survival time after HD diagnosis >1 year were treated in MOÚ during 1967-1995.
  • 337 patients were treated only by RT, 182 only by CT and 332 by RT+CT.
  • Median age at RT was 33 years, median follow-up 11 years.
  • 74 cases of SM developed in the cohort.
  • Rate ratio for NHL could not be established because of no case in the control group.
  • CONCLUSION: The relative risk of solid tumors as second malignancies increased with the time of follow-up.
  • Treatment by "risk RT" increases RR of breast cancer, colorectal cancer, gynecologic cancer and slightly thyroid cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Skarin AT, Vekeman F, Laliberté F, Afonja O, Lafeuille M, Barghout V, Duh MS: Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data. J Clin Oncol; 2009 May 20;27(15_suppl):9624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.
  • : 9624 Background: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) used to prevent or treat febrile neutropenia associated with myelosuppressive anticancer therapies.
  • According to the prescribing information, pegfilgrastim should not be administered within 14 days before or 24 hours after cytotoxic chemotherapy because of the potential for myeloid toxicity.
  • METHODS: Analysis of health insurance claims data in 2000- 2007 from > 35 large health plans across the US was conducted.
  • Patients who had a cancer diagnosis and chemotherapy within 120 days of their first pegfilgrastim injection were identified.
  • The proportion of pegfilgrastim injections that were followed by administration of chemotherapy within 11 and 9 days was calculated.
  • Analysis was also stratified by cancer type [Non-Hodgkin's lymphoma (NHL), lung, breast].
  • NHL, lung, and breast cohorts comprised 2,722, 2,772, and 4,955 patients, respectively.
  • Among all cancer types, 19.2% of pegfilgrastim injections had a chemotherapy claim within the following 11 days.
  • This pattern of use was the highest in NHL (18.9%), followed by lung (17.1%), and breast (16.2%).
  • CONCLUSIONS: Based on the retrospective analysis of this administrative claims database, the use of pegfilgrastim within 11 days of an administration of chemotherapy was observed in 15-20% of cases which is inconsistent with the recommended guidelines.
  • Pegfilgrastim use in these situations may have the potential to increase sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Cheson BD, Vose JM, Bartlett NL, Lopez A, Van der Jagt RH, Tolcher AW, Weisenburger DD, Seiz AL, Shamsili S, Keating AT: Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):8502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL).
  • : 8502 Background: Survivin is a member of the inhibitor of apoptosis proteins (IAPs) family which is responsible for preservation of cell viability and regulation of mitosis in tumor cells.
  • YM155, a survivin suppressant, has exhibited anti-tumor activity in solid tumors and non-Hodgkins lymphoma (NHL), including DLBCL patients enrolled in Phase I and Phase II monotherapy studies.
  • METHODS: Two studies enrolled 43 DLBCL patients; a Phase I study enrolled patients with solid tumors and NHL (n=1 relapsing DLBCL and n=1 refractory DLBCL), and a Phase II study enrolled refractory DLBCL patients (n=41).
  • RESULTS: Data are presented for the first 27 patients (Phase I and Phase II) who have completed therapy.
  • Two responders were refractory to their last regimen and one had relapsed approximately 2 years after stem cell transplant (SCT).
  • The most common (>4%), treatment-related grade 3/4 adverse events included anemia (16.0%) and neutropenia, fatigue, hemoglobin decrease and deep vein thrombosis (8.0% each).
  • CONCLUSIONS: YM155 is well tolerated and has modest single-agent, anti-tumor activity in relapsed/refractory DLBCL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Gordon LI, Molina A, Emmanouilides C, Raubitschek A, Darif M, Schilder RJ, Wiseman GA, White CA, Witzig TE: Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 (&lt;sup&gt;90&lt;/sup&gt;Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 (<sup>90</sup>Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL).
  • : 6574 Background: Updated time to disease progression (TTP) and duration of response (DR) are reported for responders from a multicenter phase I/II dose-escalation trial of <sup>90</sup>Y ibritumomab tiuxetan (Zevalin®) in 51 patients (pts) with relapsed or refractory CD20+ B-cell NHL.
  • Median time from diagnosis to treatment was 3.8 yrs (range, 0.7-33.1).
  • Median number of prior chemotherapy regimens was 2 (range, 1-7); 47 pts (92%) had received an anthracycline.
  • 10 pts (20%) were resistant to prior chemotherapy.
  • ORR in pts with follicular lymphoma (FL) was 85% (58% CR/CRu, 27% PR).
  • 9 pts (24% of responders) had TTP >3 yrs; 5 had FL and 4 had diffuse large cell lymphoma (DLCL).
  • 5 pts (FL, 3; DLCL, 2) are still in CR (range, 60+-74+ mos).
  • CONCLUSIONS: <sup>90</sup>Y ibritumomab tiuxetan produces high RRs and durable responses in pts with relapsed or refractory B-cell NHL.
  • Durable responses >5 years have been seen in FL and DLCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016204.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Fowler NH, McLaughlin P, Kwak L, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F: Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma.
  • : 8548 Background: Despite advances in therapy and a better understanding of the natural history of indolent non-Hodgkins lymphomas (NHL), the optimal treatment for newly diagnosed patients (pts) has not been determined.
  • While several combination chemotherapy regimens have response rates approaching 90%, toxicity is common with genotoxic drugs and secondary malignancies is a concern.
  • Lenalidomide has been shown to have single agent activity in indolent NHL, and is approved for the treatment of multiple myeloma and myelodysplastic syndrome.
  • Rituximab is effective as a single agent and in combination with chemotherapy for indolent NHL.
  • The aim of this phase II, single arm study is to evaluate the efficacy and safety of lenalidomide and rituximab in pts with untreated, stage III, or IV indolent NHL.
  • METHODS: Pts with indolent NHL who were previously untreated, with measurable disease (>1.5 cm), were eligible for enrollment.
  • Pts could receive up to 6 cycles of therapy.
  • Response was assessed after 3 cycles and at the end of therapy using the International Working Group Response Criteria.
  • RESULTS: At time of this report 17 pts have been enrolled and 14 are eligible for safety evaluation.
  • Therapy was well tolerated with the following grade 3 adverse events (AE) reported; myalgia (1 pt), rash (1 pt), peripheral neuropathy (1pt).
  • There were no grade 4 AEs.
  • There have been no reported grade 3/4 hematologic AEs.
  • After 3 cycles, one patient had unconfirmed stable disease who also was previously treated with combination chemotherapy for Hodgkin's lymphoma.
  • CONCLUSIONS: The combination of lenalidomide and rituximab has activity and is well tolerated with minimal toxicity in patients with newly diagnosed indolent lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960963.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • We report long term follow up of 71 cases of primary GI NHL treated with chemotherapy and/or surgery.
  • Median age at diagnosis was 60 (15-83).
  • 52 (73%) were DLBCL, 11 (16%) were T-cell, 8 (11%) were MALT.
  • The 8 patients with MALT were treated with single agent chemotherapy; 7 (88%) are alive at median follow up of 8.5 years (2-16).
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • Of the 63 patients with aggressive NHL, 37 (59%) remain alive & disease free at median follow up of 13 years (1-24).
  • Only 2 (18%) of the T cell lymphomas are alive & disease free.
  • 5 deaths in the DLBCL group were not related to cancer or treatment.
  • All deaths in the T cell group were due to progressive disease.
  • There was no difference in survival between patients treated with chemotherapy only and those who also underwent surgery.
  • CONCLUSIONS: Patients with aggressive primary B cell GI NHL have almost 70 % survival following anthracycline based chemotherapy.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.
  • A novel therapeutic approach is required to improve outcome in this group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Re A, Cattaneo C, Michieli M, Casari S, Spina M, Ferremi P, Mazzuccato M, Carosi G, Tirelli U, Rossi G: High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma.
  • : 6506 Background: The introduction of highly active antiretroviral therapy (HAART), has allowed the evaluation of aggressive therapeutic approaches in HIV-associated lymphoma (HIV-Ly).
  • METHODS: We report the results of a multiinstitutional program of high dose therapy (HDT) and autologous peripheral blood stem cell (PBSC) transplantation in HAART responsive pts with HIV-Ly refractory or relapsed after standard dose chemotherapy (CT).
  • Pts with active opportunistic infections (OI) or CNS lymphoma were excluded.
  • RESULTS: Twentyfive pts entered the study: 10 HD (five 1<sup>st</sup> relapse, two 2<sup>nd</sup> relapse, three refractory) and 15 NHL (eight 1<sup>st</sup> relapse, one 2<sup>nd</sup> relapse, two partial remission (PR), four refractory).
  • Two had early disease progression; one is on treatment and 14 received the BEAM regimen and PBSC transplantation with prompt engraftment in all (neutrophils and plt engraftment: 10 (8-10) and 12 days (8-18)).
  • Treatment-related toxicities (WHO grade 3-4): 3 oral mucositis (3) and 2 hepatic toxicity (3).
  • CD4 count decreased after treatment, but a trend toward recovery is seen few mo after transplant.
  • 11 are alive and 10 disease-free at 9 mo (2-24) after transplant with a projected overall survival (OS) of 64% at 2 ys.
  • The median survival of the entire series (25 pts) from the study entry was 17 mo with a projected OS of 46% at 2 ys (f-up 12 mo (3-42)).
  • CONCLUSIONS: Our data confirm on a multiinstitutional basis that HDT and PBSC transplantation is feasible and active as salvage therapy in HIV-Ly in unselected HAART responding patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. O'Connor OA: Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL).
  • : 6582 Background: Targeting of the ubiquitin proteasome pathway has proven to be a valid and efficacious approach for the treatment of several hematologic malignancies.
  • METHODS/RESULTS: To date, we have treated 25 previously treated patients with relapsed or refractory indolent lymphomas, including: 3 patients with small lymphocytic lymphoma; 9 patients with FL; 11 patients with MCL; and 2 patients with marginal zone lymphoma.
  • All but one patient had received some form of treatment prior to receiving bortezomib, including: CHOP +/- R (60%); CVP +/- R (20%); or some other purine analog based treatment program (15%), with some patients having received prior high dose chemotherapy with peripheral blood stem cell transplant (12%) or radioimmunotherapy (8%).
  • Patients were treated at a dose of 1.5 mg/m<sup>2</sup> twice weekly for two consecutive weeks with a one-week rest period.
  • No Grade III or IV toxicities were observed, save one patient that developed a grade 3 sensory and motor neuropathy.
  • Re-staging studies were routinely performed after two complete cycles of therapy.
  • All patients with small lymphocytic lymphoma were found to have stable disease after 2 and 4 cycles respectively.
  • Six of nine evaluable patients with follicular lymphoma achieved a major response, with one patient obtaining a durable complete remission.
  • The two patients with marginal zone lymphoma achieved a PR after 2 cycles of therapy, lasting now 3+ and 6+ months each..
  • Of the 10 evaluable patients with mantle cell lymphoma, 5 achieved a partial remission (response rate of 50%), with this response lasting 1+, 1+, 3+ 6 and 19 months.
  • To date no patient with small lymphocytic lymphoma/CLL has responded (n=3).
  • CONCLUSIONS: These data continue to support the biological activity of bortezomib in patients with select sub-types of indolent NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Schmitz N, Ziepert M, Nickelsen M, Wolf SP, Truemper L, Loeffler M, Ho A, Metzner B, Rosenwald A, Pfreundschuh M: Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL). J Clin Oncol; 2009 May 20;27(15_suppl):8564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL).
  • : 8564 Background: T-cell lymphomas represent a heterogeneous group of malignancies difficult to diagnose and to treat.
  • Chemotherapy regimens (CHOP-14 and CHOEP) had significantly improved outcomes of patients with aggressive B-NHL.
  • METHODS: Between 1993 and 2006 we treated 329 pts with ALK-positive ALCL (73 pts), ALK-negative ALCL (108 pts), PTCL, NOS (68 pts), AITL (28 pts), NK-/T-cell lymphoma (18 pts), and rare T-cell lymphomas on prospective studies.
  • The IPI discriminated between pts with a favorable (IPI 0, 1: OS 73%), moderate (IPI 2: OS 55%), and poor prognosis (IPI 3: OS 35%; IPI 4, 5: OS 19%) at 3 yrs.
  • Neither shortening of the treatment interval (CHOP-14) nor the addition of E (CHOEP-21 or -14) significantly improved outcome of elderly pts.
  • The MegaCHOEP protocol (Schmitz et al., CANCER 2006) failed to improve treatment results for younger pts with poor-risk disease (EFS at 3 yrs: 25.9%, 95% CI: 10.4-41.4); the prospective study comparing MegaCHOEP with CHOEP-14 was stopped for pts with T-cell lymphoma.
  • Notably, also the MegaCHOEP protocol characterized by repetitive high-dose therapy and ASCT did not result in significant improvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961019.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Braun E, Katz D, Venugopal P, Larson M, Shammo J, Fung H, Gregory S: Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy.
  • : e19529 Background: Radioimmunotherapy is a therapeutic option for relapsed or refractory indolent, follicular and transformed non Hodgkin's lymphoma and mantle cell lymphoma.
  • Although prolongued myelotoxicity has been described with use of iodine I 131 tositumomab (TOSI) and yttrium 90 ibritumomab tiuxetan (IBRI), analysis of toxicity according to patients' age at therapy still lacks.
  • METHODS: Utilizing the Rush University Medical Center database 61 subjects who received RIT between November/2003 and June/2008, either with TOSI or IBRI were divided in 2 groups according to age at time of therapy.
  • Parameters compared between groups were: Time to nadir of lowest absolute neutrophil count (ANC), time to recovery ANC above 1000/mcL, time to nadir of lowest hemoglobin levels, time to recovery to hemoglobin levels above 8g/dL, time to lowest platelet count and time to recovery to platelet count above 100,000/mcL.
  • Groups characteristics such as sex, type of RIT, presence of disease in bone marrow, FLIPI/IPI and use of G-CSF were noted.
  • RESULTS: There was no significant statistical difference between groups in time (number of days) to achieve nadir of ANC (group 1 85.3±208; group 2 50.3±19.9), nadir of hemoglobin levels (group 1 106±60.6; group 2 84±57.0) and time to nadir of platelet level (group 1 53.5±70.7; group 2 41.8±9.6).
  • There was no statistical significant difference between groups in duration of cytopenias, except for time for platelet recovery which was significant longer in group 2 using the Pearson Correlation analysis. (p=0.008). (Days for platelets recovery to levels above 100,000/mcL group 1 29.4±27.7; group 2 108.8 ±207.3).
  • One patient in group 1 and three patients on group 2 were diagnosed with MDS but were also treated with different chemotherapy regimens.
  • CONCLUSIONS: RIT should be considered a safe therapeutic modality in patients with refractory or relapsed indolent, follicular, NHL, transformed and Mantle Cell lymphoma regardless of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960911.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Armitage JO, Leonard JP, Gregory SA, Horning SJ, Zelenetz AD, Kaminski MS, Fisher RI: The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL).
  • : 6573 Background: In an overall population of 995 pts, Iodine I 131 Tositumomab was administered to 740 eligible pts with relapsed/refractory follicular grade 1/2 (n = 651) and small lymphocytic (n = 89) NHL.
  • To be eligible, pts had to have a platelet count ≥ 100,000/mm<sup>3</sup> and ≤ 25% of bone marrow involvement with lymphoma.
  • RESULTS: Demographics (for follicular vs small lymphocytic NHL): male: 55%, 64%; age >65: 23%,37%; stage III/IV: 88%,92%; median time from diagnosis: 42mo,41mo; ≥ 4 prior therapies: 30%,35%; BM involvement: 44%, 62%; tumor diameter ≥ 5 cm: 48%,44%; prior Rituximab: 45%,60%; prior radiation: 21%,17%.
  • [Figure: see text] The OR rate for follicular grade 1/2 NHL was significantly higher than for small lymphocytic (P < .001; Table) NHL, whereas the durations of response were comparable.
  • Multivariate analyses: ≥ 4 prior therapies and tumor diameter < 5 cm were significant predictors for a higher OR in pts with either follicular or small lymphocytic NHL.
  • Different factors were predictive of a higher CR rate: follicular: tumor < 5cm (P < .001), < 4 prior chemotherapies (P = .001), age ≤ 65 yrs (P = .002), and female (P = .010).
  • Small lymphocytic: no bone marrow involvement (P = .007) and > 4 yr from diagnosis (P = .036).
  • CONCLUSIONS: Among 740 pts, Iodine I 131 Tositumomab produced a significantly higher OR rate and CR rate in follicular lymphoma grades 1/2 than in small lymphocytic lymphoma.
  • However, the duration of remission was similar for responders with either diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Mones J, Coleman M, Kostakoglu L, Fiore JM, Muss D, Furman R, Stewart P, Kroll S, Goldsmith SJ, Leonard JP: A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with &gt; 25% bone marrow involvement. J Clin Oncol; 2004 Jul 15;22(14_suppl):6575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with > 25% bone marrow involvement.
  • : 6575 Introduction: The Bexxar therapeutic regimen can produce durable and complete responses in patients with relapsed/refractory low-grade NHL.
  • Virtually all previous studies of radioimmunotherapeutic agents (including Bexxar therapy) for NHL excluded patients with extensive bone marrow involvement (BMI) with tumor (>25% intertrabecular space) due to risk of excess hematologic toxicity.
  • Therefore, we evaluated Bexxar therapy specifically in this patient population to assess safety and toxicity in a dose-escalation study.
  • Three patients (estimated BMI 40-60%) received 55 cGy, with 1 having hematologic DLT concurrent with lymphoma progression with extensive BMI.
  • Non-hematologic toxicities were minimal and were similar to previous studies.
  • CONCLUSION: Treatment of patients with >25 % bone marrow involvement with Bexxar therapy was well tolerated at 45 cGy total body dose and can result in lymphoma responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016193.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Reategui RD, Beltran B, Morales D, Vera L, Quinones P, Portugal K, Desposorio C, Capellino A, Castillo J: AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • From the 48 ARL identified 44 were non Hodgkin lymphoma (NHL) and 4 were Hodgkin lymphoma.
  • From 42 systemic NHL: 38 (90,5%) were of B-cell and 4 (9,5%) were of T-cell.
  • Three groups of patients were included: 13 patients (31%) received HAART previous the diagnosis of ARL, 21 patients (50%) initiated HAART after ARL diagnosis and 8 patients (19%) did not receive HAART.
  • HAART treatment before the diagnosis of NHL increases the survival (54% versus 9,5% versus 25% respectively, p=0.048).
  • Twenty of 42 patients (47,6%) received chemotherapy.
  • This group had a better survival rate than those who did not receive chemotherapy (50% versus 4,5%, p< 0.0001) The overall response to chemotherapy was 80% with CR (n=11, 55%), PR(n=5, 25%) and PD in four (20%).
  • In a multivariate analysis, IPI score > 2, presence of B symptoms and no HAART previous ARL diagnosis were statistically associated to worse survival with p-values of 0.0001, 0.018 and 0.048 respectively.
  • CONCLUSIONS: In our study the use of HAART is effective when started before ARL diagnosis.
  • IPI score > 2, B symptoms and no HAART previous the diagnosis were unfavorable prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Buckstein R, Crump M, Shaked Y, Foden C, Nayar R, Taylor D, Bertolini F, Baruchel S, Man S, Kerbel R: Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide. J Clin Oncol; 2004 Jul 15;22(14_suppl):3016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide.
  • : 3016 Background: Relapsed aggressive Non-Hodgkin's Lymphoma (NHL) has a poor prognosis; and new treatments are needed.
  • Angiogenesis is increased in aggressive NHL, and may be a target in these diseases.
  • Low dose chronic chemotherapy (metronomic chemotherapy, MC) inhibits angiogenesis in vitro.
  • Since COX-2 may promote neoplasia and tumour angiogenesis, selective COX-2 inhibitors may have anti-tumour effects in NHL.We assessed response to MC and COX-2 inhibition and toxicity in patients (pts) with relapsed aggressive NHL following anthracycline based chemotherapy.
  • HISTOLOGY: 17 DLBCL, 2 MCL, 2 transformed (CLL+FL).
  • Median 3.3 yrs from diagnosis (range 0.9 to 9.5); 5 in 1st relapse, 4 in 2nd, 4 in 3rd, 4 in 4th and 2 with PD.
  • Median # of previous chemotherapy regimens: 3 (range 1-6); prior ASCT: 7.
  • Median time to death or last follow-up: 8.5 mos (range 1.8-17); 6/17 pts responded (1 CRu, 5 PR,ORR 35%) at a median time of 4.6 mos, and 4 remain in PR at 18, 14, 12 and 3 mos.
  • Two pts have SD and 10 have progressed at a median time of 1.9 mos (range <1-9); 7 have died of NHL.
  • Adverse events(# pts): grade 3-4 ANC (2), grade 3 plt (3), grade 3 hypertension(1), grade 3 headache(1) and grade 3 drug rash(1).
  • This regimen has been well tolerated with minimal GI toxicity.
  • CONCLUSIONS: MC with high-dose celecoxib and low dose cyclophosphamide is well tolerated and active in heavily treated relapsed aggressive NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015166.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Machover D, Delmas-Marsalet B, Gumus Y, Misra SC, Ulusakarya A, Brahimi N, Goldschmidt E, Frenoy N, Guettier C: Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx), and rituximab plus DHAOx (R-DHAOx) for treatment of patients with B-cell non-Hodgkin's lymphoma: Results from two consecutive phase II studies. J Clin Oncol; 2004 Jul 15;22(14_suppl):6681

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx), and rituximab plus DHAOx (R-DHAOx) for treatment of patients with B-cell non-Hodgkin's lymphoma: Results from two consecutive phase II studies.
  • : 6681 Background: To determine, from two consecutive phase II studies, the efficacy of oxaliplatin (L-OHP), cytarabine (ara-C), and dexamethasone (DHAOx), and DHAOx plus rituximab (R-DHAOx), in patients with non-Hodgkin's lymphoma (NHL).
  • METHODS: In Study I, treatment consisted of DHAOx (dexamethasone, 40 mg/day, days 1 to 4; L-OHP, 130 mg/m2, day 1; and ara-C, 2,000 mg/m2, every 12 hrs, day 2).
  • In Study II, treatment consisted of R-DHAOx (DHAOx plus rituximab, on day 1, 375 mg/m2).
  • Patients had failed to achieve a complete response (CR) with initial chemotherapy, were in relapse, or could not receive standard treatment.
  • RESULTS: Response to therapy: Study I: Eight patients (61.5%) achieved a CR, and 1 (8%) had a PR.
  • Responses were obtained in lymphomas of follicular, marginal-zone, mantle-cell, and diffuse large B-cell subtypes, and in patients with or without resistance to prior chemotherapy.
  • CONCLUSIONS: DHAOx and R-DHAOx are highly active for salvage treatment of patients with B-cell NHLs, and possess toxicity characteristics which compare favorably to those reported with ara-C plus cisplatin-containing regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016419.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Tulpule A, Khan AU, Mohrbacher AF, Espina BM, Buchanan L, Berman N, Gorospe G, Boswell WD, Nathwani BN, Levine AM: A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6688

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
  • Chemotherapy cycles were repeated every 21 days and given until 2 cycles beyond complete remission for a maximum of 8 cycles.
  • Baseline demographics: median age 51 years (range 20-74); all pts were CD20+ positive with diffuse large cell lymphoma in 16, high grade not otherwise specified in 2, and follicular grade 3 in 1.
  • In total, 15 pts are evaluable for response: 12 complete or clinical complete remissions (80%) have been documented; 3 pts had partial remission with one proceeding to stem cell transplant.
  • Toxicities have been primarily hematologic with transient grade 3 or 4 neutropenia in 13 (68%) pts.
  • Grade 3 anemia and thrombocytopenia were reported in 1 patient each.
  • Delays in therapy or Doxil dose reductions were required in 5 pts (26%) for grade 2 or 3 hand-foot syndrome (HFS) and in 4 others (21%) for grade 2 mucositis.
  • Other non-hematologic toxicities were grade 1 or 2 in severity.
  • CONCLUSIONS: Preliminary results show that pegylated liposomal doxorubicin (Doxil) used as replacement for conventional doxorubicin in the R-CHOP regimen is active in aggressive NHL.
  • The regimen is well tolerated with the incidence of HFS and mucositis consistent with single agent Doxil at this dose and schedule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016418.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ribeiro MJ, Patterson H, Shumate M, Harris WB, Jacobs J, Nadella P, Gillespie TW: Compliance with guidelines for elderly patients undergoing cancer therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):6148

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compliance with guidelines for elderly patients undergoing cancer therapy.
  • : 6148 Background: More than 50% of all cancers and deaths occur in individuals over age 65.Clinical decision-making for older patients may focus on patient chronological age rather than functional status, due to concerns about tolerance of more intensive and potentially curative regimens.
  • However, published data demonstrate efficacy of standard therapy with similar outcomes in elderly patients.
  • Practice guidelines could establish standards of care that, if followed, may prevent ageism in decision-making and improve clinical outcomes.
  • METHODS: This study (N=57) prospectively evaluated rate of compliance with practice guidelines, as well as toxicities and relative dose intensity (RDI) associated with therapy delivered.
  • Published evidence, NCCN guidelines for the elderly, and consensus of heme-onc clinicians at the Atlanta Veterans Affairs Medical Center (VAMC) were used to develop treatment standards for all stages/cell types of non-small cell lung cancer (NSCLC) (N=39) or non-Hodgkin's lymphoma (NHL) (N=18).
  • Consenting patients at point of clinical decision-making were enrolled into Cohort A (age ≥ 65; N=29) or Cohort B (age 50-64; N=28).
  • All patients were screened for functionality and given an objective score based on the Screening Geriatric Assessment (SGA) tool at time of enrollment.
  • For patients receiving chemotherapy, significantly more older patients (N=18; 75%) were able to finish their prescribed treatment compared to the younger cohort (N=10; 47%) (p=0.012).
  • Compliance with standards can promote optimal therapy and completion of treatment plan, avoiding dose reductions and decision-making based primarily on chronological age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Kirova YM, Dumont J, Validire P, Vincent-Salomon A, Decaudin D, Clough CB, Servois V, Savignoni A, Fourquet A: Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis. J Clin Oncol; 2004 Jul 15;22(14_suppl):6722

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis.
  • : 6722 Background:to evaluate the results of combined treatment modality with doxorubicin-based chemotherapy (C), locoregional radiotherapy (RT) and CNS prophylaxis in NHL of the breast.
  • METHODS: From 1984 to 1999, 20 female pts with diffuse large B-cell lymphoma of the breast, were treated at the Curie Institute.
  • Following biopsy-established diagnosis, complete physical exam, CAT of the chest, abdomen, pelvis, and brain, CSF, gastric endoscopy, usual blood work, bone marrow biopsy were done.
  • The C protocols were: time-modified CHOP: D1, 10, 20,35,50,65 (n=14) or MACOP-B variant (n=3), both with IT MTX and araC.
  • All pts had RT to the breast and regional nodes, within a month after C.
  • Total dose was 40 Gy in 20-22 fractions using megavoltage photons.
  • RT to CNS (18 Gy/10 fr.) was delivered in the same time.
  • The CR rate was 100% at the end of treatment.
  • Currently, 8 pts followed-up 5-15 yrs, are still alive and never experienced recurrence, 1 pt is alive with a low grade LNH.
  • CONCLUSIONS: CNS prophylaxis by IT C and CNS RT could prevent CNS relapses in pts with primary breast LNH.
  • Though all pts had CR following treatment, relapses occurred in 40% of the pts including late relapses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Bolwell BJ, Kalaycio M, Sobecks RM, Andresen S, Rybicki L, Kuczkowski E, West A, Bernhard L, Cherni K, Pohlman B: A prospective, randomized trial of stem cell mobilization with VP-16 + G-CSF with or without rituximab for B-cell lymphoid malignancies. J Clin Oncol; 2004 Jul 15;22(14_suppl):6640

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, randomized trial of stem cell mobilization with VP-16 + G-CSF with or without rituximab for B-cell lymphoid malignancies.
  • : 6640 Background: Rituximab has significant clinical activity against B- cell lymphoid malignancies.
  • The use of rituximab immediately prior to peripheral stem cell (PSC) collection might serve as an in-vivo purge to purify a collected stem cell product.
  • It is unknown, however, whether the use of rituximab at the time of PSC mobilization will alter the ability to collect adequate numbers of CD34+ cells, or have a beneficial effect on long term survival.
  • METHODS: All patients had B-cell NHL and were eligible for autologous transplantation.
  • The treatment plan consisted of VP-16 (2 gm/m<sup>2</sup>) + G-CSF, with peripheral blood stem cell mobilization beginning upon WBC recovery.
  • 68% had diffuse large B-cell lymphoma, 27% had follicular lymphomas, and 5% had high grade lymphoma.
  • The groups were balanced with respect to number of courses of prior chemotherapy, prior radiation therapy, disease status at transplant, LDH at transplant, and bone marrow involvement.
  • Engraftment was identical between the two treatment groups.
  • CONCLUSIONS: We conclude that rituximab can be given immediately prior to stem cell mobilization without short-term toxicities or a negative effect on CD34+ cell yield.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016347.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Mankan N, Madhunapantala S, Maini A: An unusual presentation of body cavity lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6699

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of body cavity lymphoma.
  • : 6699 Background: BCL (Body Cavity Lymphoma) is an uncommon primary NHL (Non-Hodgkin's lymphoms) that proliferates within serous body cavities - pleural, pericardial or peritoneal, resulting in recurrent effusions.
  • In the absence of HIV infection, it almost universally develops in the background of HHV-8/KSHV (Human Herpes Virus-8/ Kaposi's Sarcoma Herpes Virus) infection with or without EBV (Epstein Barr Virus).
  • He is heterosexual, monogamous, non-smoker and denied alcohol or intravenous drug abuse.
  • Pleural fluid LDH 4500 U/L and cytology revealed Large cell lymphoma.
  • Pleural fluid flow-cytometry demonstrated monoclonal lambda B-cell population lacking CD5 or CD10.
  • Serum PCR for HHV-8, Human T Cell Leukemia Virus 1 and 2, Hepatitis C Virus negative, serum EBV IgG positive.
  • CD4 count was 400 and CD8 was 300 with a ratio of 1.3.
  • A diagnosis of BCL was made.
  • He underwent therapeutic thoracentesis with relief of respiratory symptoms.Standard CHOP-like chemotherapy has been planned for this patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kebudi R, Berberoglu K, Unal S, Ayan I, Turkmen C, Görgün Ö: Potential role of Tc&lt;sup&gt;99M&lt;/sup&gt; - MIBI scan for detecting bone marrow metastasis in childhood solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):8570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8570 Background: The aim of this study is to evaluate the role of Tc<sup>99m</sup> - MIBI for detecting bone marrow metastases in childhood solid tumors including lymphomas.
  • The diagnosis were neuroblastoma (N) (7), Hodgkin's disease (HD) (4), non-Hodgkin's lymphoma (NHL) (2), Ewing sarcoma (ES) (3), Langerhans cell histiocytosis (LCH) (4), rhabdomyosarcoma (R) (1) and germ cell tumor (GCT) (1).
  • Bone marrow aspiration and/or biopsy was done in all children at diagnosis.
  • Tc<sup>99m</sup> - MIBI and Tc<sup>99m</sup> bone scans were obtained at diagnosis.
  • One of three patients who had abnormal MIBI scan had normal MIBI scan and negative bone marrow cytology after four courses of chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013855.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Ruan J, Martin P, Coleman M, Furman R, Glynn P, Joyce M, Cheung K, Shore T, Schuster M, Leonard J: Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL). J Clin Oncol; 2009 May 20;27(15_suppl):8525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL).
  • : 8525 Background: Targeting tumor microenvironment and angiogenesis is a novel therapeutic strategy in lymphoma.
  • Two putative anti-angiogenic regimens, RT (rituximab with thalidomide) and PEPC oral metronomic chemotherapy (prednisone, etoposide, procarbazine and cyclophosphamide) are clinically active.
  • We report phase II safety, activity, and angiogenic profiling data with the novel combination RT-PEPC in elderly patients with recurrent MCL.
  • METHODS: RT-PEPC includes an induction phase (mo 1-3) of daily thalidomide (50 mg) and PEPC with weekly rituximab x 4.
  • Translational studies assessed the angiogenic phenotypes of tumor cells, and dynamic levels of circulating endothelial and hematopoietic progenitors in response to treatment.
  • At study entry, median age (N=25) was 68 yrs (range 52-81), 24 (96%) had stage ≥ III, 16 (64%) had LDH > nl, and 18 (72%) IPI 3-5.
  • The median number of prior therapies was two (range 1 to 7), and 15 pts (60%) progressed on bortezomib.
  • Toxicities included gr 1-2 fatigue, rash and neuropathy as well as cytopenias (by design) including gr 1-2 thrombocytopenia (56%) and gr 3/4 neutropenia (56%).
  • QoL was maintained or improved on treatment.
  • Correlative studies demonstrated pre-therapy autocrine angiogenic loop in tumor cells evidenced by expression of VEGFA and VEGFR1.
  • CONCLUSIONS: RT-PEPC has significant and durable clinical activity in MCL, with manageable toxicity and maintained QoL.
  • Novel low-intensity anti-angiogenic approaches warrant further evaluation in MCL and other NHL subtypes, potentially as initial therapy in elderly patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960902.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Gerecitano JF, O'Connor O, Van Deventer H, Hainsworth J, Leonard J, Afanasayev B, Chen M, Seroogy J, Escandon R, Wolff A, Conlan M: A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL). J Clin Oncol; 2009 May 20;27(15_suppl):8578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL).
  • : 8578 Background: KSP is a mitotic kinesin essential for cell cycle progression.
  • SB-743921 (SB-921), a selective KSP inhibitor, blocks mitotic spindle assembly with cell cycle arrest in mitosis and cell death.
  • Eligible patients (pts) have relapsed or refractory HL or NHL, aggressive (a) or indolent (i), have had at least 1 prior chemotherapy (CT) regimen, and have relapsed after or were not candidates for stem cell transplant.
  • 5 pts had DLT: 1/3 at 4 (grade 3 hepatic enzymes; found retrospectively); 2/10 at 6 (both sepsis with neutropenia), and 2/7 at 7 (both grade 4 neutropenia lasting >5d) mg/m<sup>2</sup>.
  • The most frequent grade 3/4 toxicity was neutropenia: 58% at ≥MTD (-GCSF) and 42% (+GCSF).
  • Other grade 3/4 events were uncommon.
  • There was no neuropathy or alopecia >grade 1.
  • This dose density (0.43 mg/m<sup>2</sup>/d) is >2-fold higher than in the FIH trial with a q21d schedule (0.19 mg/m<sup>2</sup>/d).
  • SB-921 is well tolerated with minimal toxicity other than hematologic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962277.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Barron R, Michels SL, Reynolds MW, Tomic K, Yu J, Lyman G: Risk of mortality in patients with cancer experiencing febrile neutropenia. J Clin Oncol; 2009 May 20;27(15_suppl):9561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9561 Background: Febrile neutropenia (FN) is a serious and potentially life-threatening condition that may develop in patients with cancer treated with chemotherapy.
  • The risk of mortality from FN is not well characterized in clinical practice.
  • METHODS: Patients with cancer receiving chemotherapy in clinical practice were identified from the HealthCore Integrated Research Database, a geographically diverse spectrum of fully adjudicated longitudinal claims data from 13 health plans with over 20 million US lives.
  • Patient enrollment data, full medical care, prescription drug use and mortality (confirmed using the National Death Index) were examined for each eligible patient.
  • Patients experiencing FN were compared to propensity score-matched patients not experiencing FN within tumor types of Non-Hodgkin lymphoma (NHL), breast, lung, colorectal and ovarian cancer.
  • Study endpoints included overall mortality (anytime during follow-up) and early mortality (during a chemotherapy course).
  • Crude incidence rates of overall and early mortality were significantly higher for patients in FN group compared to controls for all tumor types [7.9/1000 person-months (PM) (95% confidence interval [CI] = 7.3, 8.5) vs. 5.6/1000 PM (CI = 5.1, 6.1), P < 0.0001; and 3.4/1000 PM (CI = 3.1, 3.9) vs. 2.4/1000 PM (CI = 2.1, 2.8), P = 0.0001, respectively].
  • Within tumor strata, lung cancer had the highest mortality rates and breast cancer had the lowest; NHL had the largest magnitude of difference between FN and controls (overall mortality: 7.2/1000 PM [CI = 5.3, 9.7] and 3.3/1000 PM [CI = 2.1, 5.1], P = 0.0035; early mortality: 3.0/1000 PM [CI = 1.8, 4.8] and 1.5/1000 PM [CI = 0.8, 3.0], P = 0.1103).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963629.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Lossos I, Craig MD, Tallman MS, Boccia RV, Conkling PR, Becerra C, Komarnitsky PB, Hamilton BL, Lewis J, Miller WH: Novel organic arsenic molecule darinaparsin: Development of IV and oral forms. J Clin Oncol; 2009 May 20;27(15_suppl):8501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Darinaparsin i.v. activity in lymphoma is being evaluated in a phase II study.
  • METHODS: Phase II trial is being conducted in patients diagnosed with advanced lymphomas who had ≥ 1 prior therapy.
  • RESULTS: The phase II study has accrued 28 lymphoma patients (21 non-Hodgkin's, 7 Hodgkin's); median age at baseline 61 years, ECOG ≤2, median number of prior therapies 3.
  • A total of 63 cycles of darinaparsin have been administered to subjects with lymphoma. No Gr.
  • 3 or higher drug-related AEs were reported.
  • Two SAEs were considered possibly drug-related (fall; neutropenic fever).
  • Phase I studies accrued 35 patients; median age at baseline 58 years, ECOG ≤2, median number of prior therapies 3.
  • Predominant tumor types include: colorectal (17), pancreatic (3), NHL (3).
  • Drug-related AEs include nausea/vomiting, fatigue, decreased appetite/anorexia.
  • CONCLUSIONS: Darinaparsin is active in heavily pretreated patients with advanced lymphoma and has been very well tolerated.
  • Oral darinaparsin is also well tolerated, and shows early activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Gutierrez M, Murgo AJ, Allen D, Turkbey I, Gardner ER, Trepel J, Chen H, Giaccone G, Doroshow JH, Kummar S: Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL. J Clin Oncol; 2009 May 20;27(15_suppl):3522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL.
  • We proposed that dual blockade of the VEGF pathway provides an added therapeutic effect compared with either agent alone.
  • OBJECTIVES: Determine the toxicity profile and the MTD of the combination of (V+B); evaluate (V) pharmacokinetics, changes in tumor vascularity by dynamic contrast enhanced MRI (DCE-MRI) and effects of (V+B) treatment on circulating endothelial progenitors and mature circulating endothelial cells.
  • The MTD is the dose level at which no more than 1 of 6 patients experience DLT during the first 2 cycles of treatment, and the dose below at which at least 2 (of ≤6) patients have DLT due to drug treatment.
  • DIAGNOSIS: pancreatic-1, NSCLC-1, colorectal-3, peritoneal mesothelioma-1, melanoma-1, NHL-1, jejunal adenocarcinoma (JAC)-1.
  • CONCLUSIONS: We decided not to escalate beyond DL 2 due to the gr 2-3 toxicities observed with chronic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961325.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL).
  • : 8582 Background: Bcl-2 family proteins are overexpressed in the majority of patients with FL and contribute to resistance to therapy.
  • It is active as a single agent and in combination with R in NHL tumor models.
  • METHODS: Patients with untreated FL who did not require immediate chemotherapy were eligible.
  • Treatment consisted of an induction cycle of AT-101 (30mg po daily × 21) and R (375 mg/m<sup>2</sup> weekly × 4) followed by up to 4 maintenance cycles of AT-101 (30mg po daily × 21) and R (375 mg/m<sup>2</sup>) every 8 weeks in nonprogressors.
  • RESULTS: 23 pts enrolled: median age 64 yrs; FLIPI 0-5: 0%/17%/65%/13%/4%; Grade 1/2: 61%/39%; bulky disease (>5cm<sup>3</sup>): 35%; stage: 1-4 4%/4%/30%/61%; bone marrow + 48%.
  • Grade 3/4 AEs that occurred in ≥2 pts: nausea 4(17%), vomiting 2(9%), abdominal pain 2(9%), fatigue 2(9%), and small bowel obstruction 2(9%).
  • CONCLUSIONS: The combination of AT-101 and R was well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Voelker MD, Chrischilles EA, Wright KB, Link BK, Park TR, Delgado DJ: Factors associated with first course chemotherapy among older patients with newly diagnosed non-Hodgkin's lymphoma: National SEER-Medicare study. J Clin Oncol; 2004 Jul 15;22(14_suppl):6118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with first course chemotherapy among older patients with newly diagnosed non-Hodgkin's lymphoma: National SEER-Medicare study.
  • : 6118 Background: Chemotherapy (CT) is indicated for some non-Hodgkin's lymphoma (NHL) patients (pts) with initial diagnosis.
  • METHODS: Using the National Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, we identified newly diagnosed NHL pts (1991-1999), age ≥66 years, with continuous non-HMO Medicare part A and B benefits.
  • First course CT was defined as a claim within 5 months of diagnosis (Dx) and whether cyclophosphamide with either doxorubicin or mitoxantrone (CH/CN) was given was determined.
  • RESULTS: Of 35,063 pts with NHL, 15,014 met inclusion criteria, and 7536 (50%) received CT (63% CH/CN).
  • Among all 15,014 pts, factors multivariately associated (p≤0.05) with receiving CT were: diffuse large cell (DLC) histology, advanced (adv) stage, younger age, white race, Charlson comorbidity index (CCI) =0, no renal disease, no anemia, no radiation therapy, SEER site and Dx year.
  • The largest associations were for DLC vs follicular histology (Odds Ratio (OR)=3.3, 95%CI: 2.9, 3.6) and age 66-70 years vs ≥86 years (OR=4.7, 95%CI: 4.1, 5.4).
  • Multivariately, receipt of CH/CN was significantly (p≤0.05) less likely with advancing age, CCI>0, anemia, heart disease, and radiation therapy.
  • Of particular interest was the rate (only 68%) of CT use in adv stage DLC lymphoma.
  • CONCLUSIONS: Nonclinical factors (younger age, white race, Dx year and SEER site) and clinical factors (DLC histology, adv stage, no radiation therapy and less comorbidity) were independently associated with receiving first course CT in this population-based study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Link MP, Devidas M, Murphy SB, Behm FG, Hutchison R: Favorable treatment outcome of children with early stage large B-cell and anaplastic large cell lymphomas. J Clin Oncol; 2004 Jul 15;22(14_suppl):8500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable treatment outcome of children with early stage large B-cell and anaplastic large cell lymphomas.
  • : 8500 Background: The non-Hodgkin lymphomas (NHL) of childhood are heterogeneous.
  • Large cell lymphomas (LCL) are relatively rare in children and sub-divided among diffuse large B-cell lymphomas (DLBCL), anaplastic large cell lymphomas (ALCL), peripheral T (PT) and other rare subtypes.
  • METHODS: We conducted a trial (POG 9219) for stage I and II NHL which accrued 396 children between 1992 and 1999.
  • One hundred fifty-six (40%) had large cell lymphoma.
  • All patients received nine weeks of chemotherapy including vincristine 1.5mg/m2 weekly for seven doses; doxorubicin 40mg/m2 and cyclophosphamide 750mg/m2 on days 1, 22 and 43; and prednisone 40mg/m2 daily for 28 days during the first 4 weeks and on days 43-47.
  • Only one patient with DLBCL developed recurrent disease and died.
  • At 5 years, the projected event-free survival (EFS) is 98 % (SE 3%), and the overall survival (OS), 98 % (SE 3%).
  • Thirty-five children with ALCL (60%) had T cell markers, and the remainder had null cell markers.
  • Nine patients with ALCL (T=5; null=4) failed treatment: three failed induction, and six relapsed from complete remission, but were effectively salvaged.
  • The projected 5 year EFS for early stage ALCL is 84 % (SE 7%) (DLBCL versus ALCL, p-value 0.02); the OS, 100%.
  • CONCLUSIONS: Nine weeks of modest intensity chemotherapy are sufficient for children with early stage DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T: Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). J Clin Oncol; 2009 May 20;27(15_suppl):e19504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003).
  • : e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis.
  • A recent phase II trial (NHL-002) of lenalidomide in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) demonstrated a 19% overall response rate (ORR) with a 7-month median duration of response (DR) in the subset of patients with DLBCL.
  • A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL that had received at least one prior treatment and had measurable disease.
  • METHODS: Patients received 25 mg oral lenalidomide once daily on days 1-21 of every 28-day cycle and continued therapy until disease progression or toxicity.
  • Median time from diagnosis was 2 years (0.4-18.6), patients had received a median of 3 prior treatment regimens (1-10) and 46 of the patients (45%) had received a prior stem cell transplant (DLBCL-stem cell).
  • Grade 3 or 4 adverse events occurring in more than 5% of patients were neutropenia (34%), thrombocytopenia (18%), asthenia (9%), anemia (8%), leucopenia (7%), back pain (6%) and dyspnea (6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Gregory SA, Leonard JP, Knox SJ, Zelenetz AD, Armitage J, Kaminiski M: The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6732

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL).
  • : 6732 Background: The Bexxar (tositumomab and iodine I 131 tositumomab [B]) therapeutic regimen yields high rates of complete and durable responses in pts with relapsed/refractory LG NHL.
  • METHODS: The safety of B therapy was reviewed for 995 pts with relapsed/refractory LG NHL, including 230 pts in 5 clinical trials and 765 pts in an expanded access program (EAP).
  • Demographics and risk factors were similar for both groups except that pts from EAP were less heavily pretreated (median, 2 vs 4 prior therapies) and more frequently received Rituximab (56% vs 17%).
  • All adverse events (AEs) occurring within 13 wks of treatment were reported, regardless of relationship to study drug.
  • RESULTS: Most frequent hematologic (heme) AEs were grade (gr) 3/4 neutropenia (41%), thrombocytopenia (37%), and anemia (12%), requiring supportive care in 27% of pts (G-CSF, 12%; erythropoietin, 10%; platelet transfusions 12%; packed RBCs, 16%).
  • Significant (P < .001) predictors of gr 3/4 heme toxicity were number of prior therapies, baseline blood counts, prior fludarabine, and degree of bone marrow (BM) involvement.
  • Infusions were well tolerated (2% gr 3/4 infusion AEs).
  • Delayed toxicities included HAMA responses (cumulative incidence, 9.8% at 2 yr; 10.1% at 5 yr) and hypothyroidism (cumulative incidence, 8.7% at 2 yr; 16.6% at 5 yr), and 35 pts developed MDS/AML after B therapy.
  • The data do not suggest an increased risk of MDS/AML over that seen in pts heavily pretreated with leukemogenic therapies.
  • These data suggest that the risks associated with B therapy are outweighed by the clinical benefits in pts with relapsed/refractory LG NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Kim J, Kim E, Sohn B, Yoon D, Yoo C, Kim S, Lee D, Kim S, Lee J, Suh C: BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):7097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients.
  • : 7097 Background: The objective of this study was to compare the efficacy and toxicity of two high-dose regimens for autologous stem cell transplantation (ASCT) in patients with non-Hodgkin's lymphoma (NHL): BEAM (BCNU, etoposide, cytarabine, and melphalan) and BuCyE (busulfan, cyclophosphamide, and etoposide).
  • METHODS: We analysed 65 NHL patients, who underwent high-dose chemotherapy with BEAM (N=43) or BuCyE (N=22), followed by ASCT, at the Asan Medical Center.
  • RESULTS: Median age was 46 years (range: 15-68), and baseline characteristics, such as gender, International Prognostic Index (IPI), age adjusted IPI, stage and status of disease at ASCT, and median number of infused CD 34+cells/kg were well balanced between groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961268.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Khorana AA, Culakova E, Lyman GH, Francis CW: Incidence of thromboembolic events in a prospective nationwide registry of cancer patients initiating systemic chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):8019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of thromboembolic events in a prospective nationwide registry of cancer patients initiating systemic chemotherapy.
  • TED rates may be further increased with chemotherapy.
  • We conducted a prospective study to determine incidence of symptomatic TED in cancer outpatients on chemotherapy, and a retrospective analysis of TED rates in cancer patients hospitalized with febrile neutropenia.
  • METHODS: Cancer outpatients initiating chemotherapy were registered at 137 community practices nationwide, and followed prospectively for 4 cycles.
  • Pulmonary embolism occurred in 9 patients, and 28 patients developed deep venous thrombosis for a TED incidence of 2% over a median follow-up of 2.3 months.
  • Other sites included ovarian cancer (n=3/147, 2%), NHL (n=3/174, 1.7%), colon (n=3/193, 1.6%), and breast (n=7/672, 1%).
  • Patients with TED reported a chemotherapy delay of ≥ 7 days in 44% compared to 23% in the study population (p=0.003, OR 2.73).
  • An additional 1.3% develop TED if hospitalized with complications of chemotherapy.
  • TED can lead to significant delays in chemotherapy.
  • Trials of prophylactic anticoagulation in cancer patients on chemotherapy are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015837.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Park B, Kim W, Eom H, Kim J, Oh S, Suh C: A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma.
  • : 8559 Background: Gemcitabine combined with cisplatin has been known as an effective regimen for lymphoma treatment in salvage setting.
  • We investigated the response rate and toxicity of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOx) for recurrent or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), looking for the more effective and less toxic therapy.
  • METHODS: Patients with recurrent or refractory diffuse large B-cell NHL or mantle cell lymphoma, measurable disease, and more than one previous chemotherapy regimen were eligible.
  • Treatment consisted of gemcitabine 1000 mg/m<sup>2</sup> intravenously (i.v.) on Days 1 and 8, ifosfamide 2000 mg/m<sup>2</sup> i.v. on Day 1, dexamethasone 40 mg orally on Days 1-4, and oxaliplatin 130mg/m<sup>2</sup> i.v. on Day 2, every 21 days.
  • Patients could then proceed to stem cell transplantation (SCT) or receive up to six treatment cycles.
  • The median age of the patients was 54 years (range, 18-75 years) and most had diffuse large-cell lymphoma.
  • The RR after completion of all protocol chemotherapy including SCT was 44% (10 CR, 2 PR).
  • In total 88 cycles of GIDOx, grade 3 and 4 neutropenia occurred in 33% and 16% of cycles, respectively.
  • Grade 3 and 4 thrombocytopenia occurred in 14% and 16% of cycles, respectively.
  • CONCLUSIONS: GIDOx is an active salvage regimen in aggressive B-cell NHL and can be administered with acceptable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Alarcon-Rozas AE, Cardenas RA, Villacres K, Salas F, Guevara J, Hernandez E: Study of prevalence of seropositivity from seven different virus associated to non Hodgkin's lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6689

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of prevalence of seropositivity from seven different virus associated to non Hodgkin's lymphoma (NHL).
  • - NHL is the 5th leading cause of cancer mortality in Peru and it is well known that some virus are associated to NHL like EBV for Burkitt and posttransplantation lymphoma as well as HTLV-I for ATLL.
  • There are emerging virus related to NHL like HCV, CMV, HIV, and HSV.
  • The purpuse of this study is to know the prevalence of IgG and IgM viral seropositivity or by ELISA in some cases in new NHL patients.
  • PATIENTS AND METHODS: - We collect 60 new patients with confirmed NHL by pathology at Guillermo Almenara Hospital and HMC from 6/99 to 6/02, we took a blood sample for analizing the seropositivity measuring the level of IgG and IgM for HSV-I, HSV-II, EBV and CMV or by ELISA for HCV, HTLV-I and HIV.
  • We do not accept NHL patients already in chemotherapy because many of them could have been infected by some of these virus during the neutropenic period.
  • - It is remarkable the high incidence of T cell and extranodal NHL, different from the epidemiology of NHL in occidental countries.
  • We need a case-control study to determine the significance of these results as well as molecular analisis in order to know if the insertion of viral genome is really in the lymphoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Weycker D, Hackett J, Edelsberg J, Oster G, Glass A: Duration of G-CSF therapy and risk of hospitalization for neutropenia or infection. J Clin Oncol; 2004 Jul 15;22(14_suppl):6731

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duration of G-CSF therapy and risk of hospitalization for neutropenia or infection.
  • : 6731 Background: Clinical trials have demonstrated that 10-12 days of granulocyte-colony-stimulating factor (G-CSF) prophylaxis is effective in reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
  • METHODS: Using a large US health-insurance claims database, we identified all adults with non-Hodgkin's lymphoma (NHL) who received myelosuppressive chemotherapy and G-CSF prophylaxis between 1998 and 2002; unique cycles of chemotherapy were identified.
  • Pooling all such cycles, we used a GEE (Generalized Estimating Equation) model (with a logistic link function) to examine the relationship between duration of G-CSF prophylaxis and risk of hospitalization for neutropenia or infection, adjusting for potential confounders.
  • Risk of hospitalization was significantly lower (OR: 0.81, p<0.01) with each additional dose of G-CSF, up to a maximum of 14 doses; patients receiving 5 doses of G-CSF, for example, were approximately 3 times (OR: 2.9, 95%CI 1.5-5.5) more likely to be hospitalized than those receiving 10 doses.
  • A higher Charlson Index also was associated with a higher risk of hospitalization (OR: 1.25, p<0.01).
  • CONCLUSIONS: Among NHL patients receiving G-CSF prophylaxis, risk of hospitalization is related to duration of therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014497.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Khanna C, Cozzi E, Sharpee R, Vail D, Graham J, Kitchell B, Rusk T: A randomized placebo-controlled pre-clinical trial of the anti-angiogenic thromobspondin-mimetic peptide ABT-526 plus Lomustine chemotherapy versus Lomustine chemotherapy alone in pet dogs with relapsed non-Hodgkin's lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):3088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized placebo-controlled pre-clinical trial of the anti-angiogenic thromobspondin-mimetic peptide ABT-526 plus Lomustine chemotherapy versus Lomustine chemotherapy alone in pet dogs with relapsed non-Hodgkin's lymphoma.
  • METHODS: To assess the safety and efficacy of ABT-526 when given in combination with Lomustine chemotherapy, 94 pet dogs with naturally occurring non-Hodgkin's lymphoma (NHL), in their first relapse, were entered to a prospective randomized placebo controlled double-blinded clinical trial.
  • Response rate, duration of response, time to progression, and incidence of toxicoses were compared between groups.
  • Lomustine associated dose-limiting toxicities, including neutropenia, thrombocytopenia, gastroenteritis, and elevated alanine transaminase, were similar between treatment groups.
  • No significant difference in the objective response rate was seen between treatment groups [ABT-526+Lomustine = 23/49 (47%) vs placebo+Lomustine = 23/37 (62%); P>0.25].
  • The time to progression for responding cases was also significantly greater in patients receiving ABT-526 plus Lomustine compared to placebo plus Lomustine (41 days vs 21 days; P=0.047).
  • CONCLUSIONS: The significant activity of ABT-526 demonstrated in this preclinical trial appears to be associated with the maintenance of Lomustine induced treatment responses.
  • Further studies of ABT-526, in this relevant naturally occurring model of NHL, are warranted and may be used to define biomarkers that predict responsiveness to antiangiogenic therapy and evaluate the activity of ABT-526 in combination with conventional and novel treatment agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Fiore JM, Furman RR, Schuster MW, Kroll SM, Goldsmith SJ: Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL).
  • : 6518 Background: The sequential combination of chemotherapy and radioimmunotherapy offers a novel strategy for the initial management of NHL.
  • Tositumomab and iodine I 131 tositumomab (Bexxar) have been demonstrated to have substantial clinical activity in both untreated and relapsed/refractory low-grade NHL.
  • METHODS: Patients with previously untreated, advanced low-grade NHL were treated with IV fludarabine 25 mg/m<sup>2</sup>/day for 5 days, every 5 wks for 3 cycles followed in 6 to 8 wks by Bexxar therapy.
  • RESULTS: Between August 1998 and June 1999, 38 pts (51% follicular mixed, 49% follicular small cleaved) were enrolled and 97% had stage III/IV disease.
  • Thirty-five subjects received both fludarabine and Bexxar therapy.
  • Three patients came off study before or during fludarabine therapy (one due to cytopenias, 2 unrelated to toxicity or lymphoma progression).
  • Following Bexxar therapy, 35 of 35 subjects (100%) had a response including 83% CR.
  • With a median follow-up of 4.4 years, median progression-free survival has not been reached, and 72% of pts achieving a CR remain in CR.
  • Among 35 evaluable pts, grade 4 neutropenia, thrombocytopenia, and anemia were noted in 34%, 29%, and 3% of pts, respectively.
  • Four (12%) pts developed elevated TSH and 2 (6%) pts developed HAMA.
  • No pts have developed MDS/AML.
  • CONCLUSIONS: Fludarabine followed by Bexxar therapy appears to be a highly effective and well tolerated regimen for the initial therapy of advanced follicular NHL, producing long-term durable complete remissions in the majority of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016917.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Narayanan G, Ratheesan K, Madhavan J, Rajan B: Primary orbital lymphoma -A review of 25 cases from India. J Clin Oncol; 2004 Jul 15;22(14_suppl):6721

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary orbital lymphoma -A review of 25 cases from India.
  • : 6721 Primary orbital Non Hodgkin's lymphoma (NHL) accounts for about .01% of all lymphomas and 10% of all orbital tumors.
  • AIM: The purpose of this study is to review our Institutional experience with primary orbital lymphoma.
  • MATERIAL AND METHODS: Between 1995-2000, twenty-five patients were treated for orbital lymphoma at our Institute.
  • All patients had biopsy proven NHL.
  • RESULTS: The median age at diagnosis was 48 years (range 19-83), there were 17 males and 8 females.
  • The histology was low grade in 9 patients, intermediate or high grade in 16 including 2 with mantle cell lymphoma and 1 with MALT lymphoma.
  • Fifteen patients received radiotherapy, the dose ranged from 20-50 Gy with a median of 40 Gy, 2/3 rd received a dose of 40-45Gy.
  • Chemotherapy was given to 7 patients (CHOP, COP, Leukeran).
  • Four patients recurred either locally or in the opposite eye and received chemotherapy or radiotherapy.
  • CONCLUSIONS: Orbital lymphoma is curable, and radiotherapy is a safe and effective local treatment in the management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014681.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD: Phase II trial of rituximab and short duration chemotherapy followed by &lt;sup&gt;90&lt;/sup&gt;Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):6519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of rituximab and short duration chemotherapy followed by <sup>90</sup>Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial.
  • : 6519 Background: First-line treatment with combination chemotherapy + rituximab improves molecular complete remission (CR) rates and lengthens remission duration in patients (pts) with follicular NHL.
  • In a previous phase II trial, we demonstrated a high CR rate with short course chemotherapy + rituximab (CHOP-R or CVP-R).
  • METHODS: Previously untreated pts with follicular lymphoma (grades 1-3) and stages II-IV were eligible.
  • 22 pts have completed therapy and been restaged: 19 pts (86%) are in CR, with 3 PR's. 10 pts with PR converted to CR after <sup>90</sup>Y-ibritumomab tiuxetan.
  • No unexpected toxicity was seen during CHOP-R therapy.
  • <sup>90</sup>Y-ibritumomab tiuxetan caused no grade 3/4 nonhematologic toxicities.
  • CONCLUSIONS: First-line CHOP-R followed by <sup>90</sup>Y-ibritumomab tiuxetan is highly active and well tolerated in pts with follicular NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016918.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Razzouk BI, Hockenberry M, Hinds PS, Rackoff W, Hord JD: A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):8527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy.
  • : 8527 Background: This study was designed to assess the effect of epoetin alfa (EPO) on hemoglobin (Hb) and quality of life (QOL) in children with cancer receiving myelosuppressive chemotherapy (CT).
  • METHODS: This was a double-blind, placebo (PBO)-controlled study of pts aged 5-18 y with malignant solid tumors (ST), Hodgkin's lymphoma (HL), acute lymphocytic leukemia (ALL), or non-Hodgkin's lymphoma (NHL) and Hb <12 g/dL.
  • Pts were stratified by tumor type (ST/HL or ALL/NHL) and randomized 1:1 to receive IV EPO 600 U/kg or PBO weekly for 16 wks.
  • Primary end point was pt-reported Peds Quality of Life Inventory (PedQL-I™) Total Score; secondary endpoints included parent-reported PedsQL-I and pt- and parent-reported PedsQL Cancer Module (PedsQL-CM: Cognitive Problems, Communication, Nausea, Pain and Hurt, Physical Appearance, Procedural Anxiety, Treatment Anxiety, Worry), Hb, and transfusions.
  • RESULTS: 222 pts (111 EPO, 111 PBO) were included in the intent-to-treat analysis: 27 HL, 98 ST, 75 ALL, and 22 NHL.
  • Pt- and parent-reported Cognitive Problems scores were improved in ALL/NHL pts receiving EPO vs PBO (P=.026 and P=.014, respectively), but no other PedsQL-CM domain.
  • CONCLUSIONS: IV EPO was well tolerated in pediatric cancer pts.
  • Although few differences between QOL scores were detected, there was significant improvement in QOL in pts aged 5-7 y and improved Cognitive scores in ALL/NHL pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Robertson C, Boyle P, Kerr DJ: Determinants of anemia in cancer patients receiving chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):9719

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of anemia in cancer patients receiving chemotherapy.
  • Details of one cycle out of all chemotherapy cycles were recorded retrospectively in 41,114 patients.
  • Risk of anemia was investigated through the effects of gender, age, chemotherapy type, country, cycle number and year of treatment with logistic regression (with 95% confidence intervals (CI)).
  • Eight different tumor types were considered: breast, Small Cell lung (SCL), Non Small Cell lung (NSCL), ovarian, Acute Myeloid Lymphoma (AML), Non Hodgkin Lymphoma (NHL), Hodgkin Disease (HD), Multiple Myeloma (MM).
  • RESULTS: Across all tumor types anemia was reported in 67% of the patients and in > 95% in AML patients.
  • Incidence increased over time for breast cancer, SCL, NSCL, NHL and MM.
  • Age had no independent effect except for NHL with less anemia in patients > 40 years.
  • Apart from MM and NHL a clear risk tendency for anemia to increase with subsequent cycles is observed.
  • CONCLUSIONS: Anemia affects the majority of cancer patients receiving chemotherapy, being more frequent in men and during subsequent chemotherapy cycles.
  • Research is required to better understand the frequency differences noted across countries in Europe and to identify patients at high risk, particularly in the initial cycle, since prevention and/or treatment measures are readily available.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Roussel M: Non-Hodgkin's lymphoma in women with breast cancer: A retrospective study of 46 patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6670

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in women with breast cancer: A retrospective study of 46 patients.
  • Improvement in screening and treatment strategies increased long-term survivors.
  • Those women are then at risk for second malignancies, including non-Hodgkin lymphoma (NHL).
  • Currently, no genetic or treatment-related risk factors have been demonstrated.
  • In the Curie's Institute cohort of BC, we analyzed women with second NHL and tried to assess risk factors.
  • In the database, we recorded 57 women with NHL.
  • RESULTS: Median age at diagnosis of BC was 57 yrs.
  • 78.3% received radiotherapy and 41.3% systemic therapy.
  • Median delay of apparition for NHL was 7.8 yrs (range 1.3-26.7).
  • B cells lymphomas were mainly represented with 50% follicular lymphoma and 30.4% large cells lymphoma.
  • There was no recurrent cytogenetic abnormality.
  • All pts received appropriate treatments.
  • 22 (47.8%) died of the lymphoma.
  • Survival was related to histological grade.
  • A 3/1 case control study matched on age, date of BC diagnosis and survival didn't show treatment-related risk factor.
  • CONCLUSION: NHL is a second primary malignancy in women with breast cancer.
  • There is no evidence in our cohort for treatment-induced NHL.
  • [Figure: see text] S: surgery, RTE: external radiotherapy, CT: chemotherapy, H: hormonotherapy No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Aggarwal S, Prakhar P, Kohli S, Negi A, Jauhari M, Bhalla S: Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India. J Clin Oncol; 2009 May 20;27(15_suppl):e19566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India.
  • Out of a total of 16,500 cases, NHL was reported in 154 (0.93%)cases.
  • The type of NHL was B-Cell type (CD-20+ve) in 132(85%) and T-Cell type (CD 3+ve) in 22 (15%) cases.
  • In extra-nodal group of NHL patients the no.
  • Out of 77 extra-nodal cases, 31(20%) were GIT NHL (Stomach -16, Colon-8, Ileum-4, and Duodenum-3) and out of the rest 46 extra-nodal cases the site of origin was - head & neck-14, skin n soft tissues -8, primary CNS-6, testicular-4, para-spinal- 3, breast mass-3, perinephric-2, bones-2 and 1 each in cervix, lung mass, liver and cervical plexus.
  • METHODS: A detailed analysis of 31 GIT NHL cases was carried out.
  • 28 out of 31 were B-Cell type and 3 were T-Cell type.
  • 26 out of 31 were diffuse large cell variety, 2 were mixed small & large cell variety and 1 MALT variety.
  • In 2 patients the type of lymphoma could not be ascertained.
  • Bone marrow infiltration was present in 2 out of 31 cases of GIT Lymphoma.
  • Surgery was carried out in 15 of 31 GIT NHL cases and these were arising from Colon, Ileum and Duodenum.
  • No surgery was performed in patients with stomach lymphoma.
  • RESULTS: Of all the extra-nodal cases chemotherapy was given to 39 patients - R-CHOP = 20 patients, CHOP = 13 patients, high dose MTX in primary CNS NHL = 6 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961061.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Nagai H, Kusumoto S, Sawada K, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Omachi K, Ogura M, Hotta T: Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.
  • : e19501 Background: Although cladribine has been reported to be one of active purine analogs against indolent B-cell non-Hodgkin's lymphoma (B-NHL), there are few reports of combination usage of cladribine and rituximab.
  • We conducted a multicenter phase II study to investigate efficacy and toxicity of cladribine with rituximab (R-2-CdA) therapy for relapsed indolent B-NHL.
  • METHODS: Eligibility criteria were as follows: relapsed pts with indolent B-NHL from systemic chemotherapy, ages less than 75 years; PS 0-2 by ECOG's scale.
  • RESULTS: A total of 20 out of 45 planned patients were enrolled and received R-2-CdA therapy from Apr 2005 to Jul 2007.
  • Histologies included 16 follicular lymphomas, 2 MALT lymphomas, 1 nodal marginal B cell lymphoma, and 1 lymphoplasmacytic lymphoma.
  • Median PFS was 20.1 months (5.6-32.9 months) at a median follow-up time of 27 months.
  • Severe neutropenia and thrombocytopenia of grade 3 or 4 were observed in 15% and 10% respectively.
  • CONCLUSIONS: R-2CdA therapy was demonstrated to have high activity with durable PFS and acceptable toxicity in relapsed indolent B-NHL, even if patients were previously treated with rituximab.
  • Although a large-scaled further trial remains to be needed, R-2-CdA therapy could be a good option of salvage therapy in relapsed indolent B-NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Flowers C, Sinha R, Kaufman J, Shenoy P, Lewis C, Bumpers K, Rogatko A: Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results. J Clin Oncol; 2009 May 20;27(15_suppl):8577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
  • : 8577 Background: Adding rituximab (R) to chemotherapy improves survival for patients (pts) with follicular lymphoma (FL) and other indolent non-Hodgkin lymphomas (NHL), but not all pts respond.
  • We developed a phase I/II trial to test if adding B to RCHOP with modified vincristine dosing can be well-tolerated and yield a high CR rate.
  • METHODS: Untreated pts with indolent NHL and indications for treatment based on GELF criteria or FLIPI ≥3 received R 375mg/m<sup>2</sup>, cyclophosphamide 750mg/m<sup>2</sup>, doxorubicin 50mg/m<sup>2</sup>, vincristine 1.4mg/m<sup>2</sup> (capped at 1.5mg) on day 1, B 1.0- 1.6mg/m<sup>2</sup> days 1 and 8, and prednisone 100mg days 1-5 for 6-8 cycles.
  • The maximum tolerated dose (MTD) was defined as the regimen at which <30% grade3 non-hematological or grade ≥4 hematological toxicity (>14 days) occurs.
  • Functional Assessment of Cancer Therapy (FACT) Neurotoxicity (11-item; 4 point scale), EMG, nerve conduction velocity and epidermal nerve fiber density measures were taken at baseline and after cycle 4.
  • RESULTS: 11 pts with FL (n=6) or other indolent NHL enrolled in phase I.
  • Treatment was well tolerated.
  • Neuropathy occurred in 4 pts (36%), with 2 grade 1, 1 grade 2 and 1 grade 3 toxicity ( Table ).
  • Grade 4 neutropenia occurred in 4 pts (36%), but none >14 days.
  • 3 continue on treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962274.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Roberts AW, Wilson W, Gandhi L, O'Connor OA, Rudin CM, Brown JR, Xiong H, Chiu Y, Enschede S, Krivoshik AP: Ongoing phase I studies of ABT-263: Mitigating Bcl-X&lt;sub&gt;L&lt;/sub&gt; induced thrombocytopenia with lead-in and continuous dosing. J Clin Oncol; 2009 May 20;27(15_suppl):3505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ongoing phase 1 studies of ABT-263 show anti-tumor activity in CLL and some lymphomas (Wilson W et al, ASH. 2008).
  • Platelet nadir occurred on days 3-5 on 14/21 d dosing with each exposure to drug, was proportional to starting platelet count and recovered during therapy due to compensatory increased megakaryopoiesis.
  • METHODS: CD with a 7 d lead-in dose was explored (150, 150 or 100 mg lead-in doses) with dosing at 200 and 275 mg, 225 and 325 mg, or 125 and 250 mg in studies M06-814 (NHL), M06-822 (SCLC), and M06 873 (CLL), respectively.
  • 2 DLTs were observed for CD, 1 pt per study M06-814 (275 mg) and M06-873 (200 mg) experienced grade 4 (TCP).
  • While CD enrollment and time on study is still limited, anti-tumor activity includes 1 unconfirmed partial response (68% CT regression) in a SLL pt at 275 mg and 3 CLL pts with ≥50% lymphocyte reduction for ≥2 months.
  • Optimal dosing regimens may vary between tumor types especially where marrow infiltration is a feature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961281.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Jurczak W, Wywial A, Zaluska A, Pasowicz M, Skotnicki AB: Extranodal masses compressing spinal cord in Hodgkin's disease and follicular lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6728

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal masses compressing spinal cord in Hodgkin's disease and follicular lymphoma.
  • In case of low grade lymphomas (like follicular lymphoma - FL) in advanced clinical stage, they may be even less thorough.
  • Therefore the disease within vertebral column -best visualized by magnetic resonance studies (NMR) -may be missed at diagnosis.
  • METHODS/RESULTS: During the last 2 years 3 cases of infiltration of vertebral column (extranodal masses localized within the vertebral canal, compressing but not infiltrating the spinal cord) were diagnosed in over 100 patients treated for HD and FL at that time.
  • In a FL patient they were diagnosed at presentation, while in two HD cases they were found 6 and 9 months after completing the first line therapy, being the cause of early relapse (primary resistance?
  • ). They were not reported in a routine 3- monthly CT scans performed in purpose to monitor non-progressive residual masses.
  • Radiotherapy -if used in the first line therapy -seems to be a feasible and effective treatment: FL patient is in CR, since IFRT was applied after chemoimmunotherapy (6 cycles of cladribine and cyclophosphamide combined with a standard dose of Rituximab, recycled at day 21); one HD patient treated with 6 cycles of ABVD and Mantle field radiotherapy relapsed evidently below the irradiated field.
  • However both HD cases developed resistance despite second line regimens and high dose chemotherapy supported by autologous stem cell transplant.
  • CONCLUSIONS: Therefore we conclude, that HD and FL patients with any neurological signs or symptoms at diagnosis should be considered as likely candidates for NMR imagind studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014665.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR, Horning SJ, Eastern Cooperative Oncology Group, Cancer and Leukemia Group B: Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL).
  • : 6502 Background: Despite high overall response rates, indolent NHL is characterized by continuous relapse.
  • E1496 evaluated the ability of two years (yr) of maintenance rituximab to prolong progression-free survival (PFS, progression or death) after chemotherapy.
  • METHODS: Eligible patients (pt) included stage III-IV follicular grade 1 and 2 (small cleaved, mixed) and small lymphocytic NHL.
  • The rituximab (n=154) and observation (n=149) pt were respectively balanced for age (59, 56 yr), residual disease (58%, 55% minimal), histology (77%, 77% follicular) & tumor burden (62%, 67% high) as well as gender, stage, marrow involvement and International Prognostic Index.
  • CONCLUSION: Maintenance rituximab significantly prolongs PFS after CVP chemo in pt with advanced indolent NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016889.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Rubio-Martínez A, Recasens V, Martos C, Montañés A, García-Carpintero G, Gómez-López L, Rubio-Félix D, Giraldo P: Predictive factors to develop a second neoplasia in a Hodgkin disease cohort patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6707

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6707 Background: Hodgkin's lymphoma (HL) is a rare malignancy, incidence rate (IR): 2.4/105 inh/y, 85% can be cured.
  • The importance of late effects of therapy have become more apparent.
  • VARIABLES: demographic data, date of HL diagnosis, histological subtype, stage, treatment schedule (chemotherapy, radiotherapy, combined), date SM diagnosis, subtype and location of cancer.
  • Cohort was stratified according to age, gender and schedule of therapy.
  • Radiotherapy 16.1% (mantle 50%, inverted-Y 11.8 %, both: 1.6%;cobalt 59.3%, linear accelerator 4.2%; total dose 20-36 Gy), chemotherapy 39.8% (ABVD 14.4%, MOPP 15.5%, CMOPP 23.7%, CMOPP/ABVD 18.6%, ABVD/MOPP 15.2%), combined 44%.
  • HL relapsed: 10.1%, mean time: 49 m.
  • Developed a SM 15(12.7%), mean 102.3 m; range 9-285: 11 a non-hematological neoplasia: adenocarcinoma (colon, breast, lung, oropharynx, skin, cavum, parotida. thyroid) and 4 a hematological neoplasia (AML and NHL).
  • The global risk of cancer in HL was 10.0 and 6.5 when only non hematological tumor were considered.
  • CONCLUSIONS: The incidence of SM among long-time survivors of HL is higher than in normal population.
  • In other essays the major risk has been observed in patients treated with radiotherapy either alone or combined with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014611.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement